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1. Summary  
 
The aim of the thesis is to investigate the potential use of mutant 
replication deficient influenza B viruses with impaired interferon 
antagonistic function as live attenuated vaccines. 
We generated several influenza B viruses containing either carboxy-
terminal truncated NS1 proteins of different length or completely lacking 
the NS1 ORF (∆NS1-B) employing reverse genetics on Vero cells. Due to a 
unique, single amino acid mutation M86V in the influenza B M1 protein 
viral growth in Vero cells was increased, enabling the rescue of a ∆NS1-B 
virus growing to titers of 8 logs.  All viruses showed restricted growth in 
human alveolar epithelial cells (A549) and in 6 day old human 
macrophages. The attenuated phenotype of the viruses was associated 
with induction of antiviral (IFN-α) and pro-inflammatory cytokines (TNF-α, 
IL-6 and IL-1β) early after infection. All vaccine candidates were 
replication deficient, did not provoke any clinical symptoms and induced 
neutralizing antibody response in mice and ferrets. Complete protection 
against homologous challenge with wild-type virus was accomplished after 
a single intranasal immunization.  
So far, the lack of a ∆NS1-B virus component growing to high titers in cell 
culture has been limiting the possibility to formulate a trivalent vaccine 
based on deletion of the major interferon antagonist. Our study                       
closes this gap and paves the way for the clinical evaluation of a seasonal, 
trivalent, live replication-defective ∆NS1 intranasal influenza vaccine. 
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4. Introduction 
 
4.1. Influenza virus  
4.1.1. Structure 
 
Influenza viruses belong to the virus family of Orthomyxoviridae, 
containing eight single-stranded genes in negative polarity. Three types of 
influenza virus (A, B and C) occur in nature, whereas only influenza virus 
A and B undergo antigenic drift (A and B) and antigenic shift (only A), 
defining the epidemiologic and pandemic nature of these viruses and 
causing significant morbidity and mortality in humans. In contrast to 
influenza A virus and influenza B virus, as recently discovered, influenza C 
virus lacks an animal reservoir and is therefore not of major interest 
concerning outbreaks in humans (Lamb, 1989, Osterhaus et al., 2000, 
Palese, 2007). 
All influenza viruses’ posses a common structure (Fig.1). The virus is 
surrounded by a host derived lipid membrane in which the two viral 
surface glycoproteins haemaglutinin (HA) and neuraminidase (NA), and 
the ion channel protein (M2) are embedded. The matrix protein 1 (M1) 
underlies the lipid envelope forming a protein layer. In the core, each RNA 
segment is encapsulated by the nucleoprotein (NP) and the three viral 
encoded polymerase proteins (PB1, PB2 and PA) forming the 
ribonucleoprotein complex (RNP complex).  These RNA segments of 
influenza A and B possess highly conserved 5’ and 3’ complementary non 
coding regions (NCR) of 16 & 15nt in length for influenza A and 10 & 10nt 
for influenza B viruses, respectively. The NCR are hybridizing with each 
other, forming a “panhandle” structure (Baudin et al., 1994, Flick & 
Hobom, 1999). At the same time they are recognized by the viral 
polymerase complex serving as a promoter controlling the transcription of 
vRNA. The RNA genome of Influenza A and B virus consists of eight genes 
coding for 11 proteins due to different open reading frames (ORF) 
(Compans RW, 1974). Whereas influenza A virus is coding for an 
additional protein termed PB1-F2, influenza B virus differs from A in 
expressing an NB protein from the NA ORF (Table 1) (Betakova et al., 
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1996, Chen et al., 2001, Imai et al., 2004, Imai et al., 2003).  The nuclear 
export protein (NEP/NS2), formerly believed to be non structural, is also 
located in the virus particle in a very low copy number (Lamb & Choppin, 
1979, Richardson & Akkina, 1991). The small non structural protein 1 
(NS1) is only expressed in infected cells and is not being packaged into 
the virion. 
 
Fig. 1: Schematic drawing of the influenza virus structure 
 
Influenza B viruses are mostly indistinguishable from the A viruses by 
electron microscopy.  In contrast to influenza A virus they have four viral 
proteins inserted in their lipid membrane, the HA, NA, NB and BM2, 
whereas the M1 and the RNP complexes make up the interior of the 
particle.   
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Table 1: Illustration of gene segments of Influenza A and B  (Lamb, 2001)     
    
 
 
 
4.1.2. Replication 
 
Influenza virus binds to N-acetyl-neuraminic acid (sialic acid) containing 
receptors on the host cell surface to initiate viral infection and replication 
via it’s HA protein as illustrated in Fig. 3 (Palese, 2007). Upon adsorption 
to the receptor the viral particle enters the cell by receptor mediated 
endocytosis and is internalized into endosomes. Due to the acidic 
environment in the endosomes, the HA protein undergoes a 
conformational change, leading to fusion of the viral and cellular 
membrane (Stegmann, 2000). The viral compartment also gets acidified 
by M2 protein acting as an ion channel resulting in uncoating (Pinto et al., 
1992). This uncoating event leads to the dissociation of the M1 protein 
from the RNP complex and successively the release of the viral genome 
(in form of vRNPs) into the cytoplasm. The vRNPs, mediated by the 
nuclear localisation sequences (NLS) of the NP and polymerase proteins, 
are then imported into the nucleus for replication and transcription by the 
virus’ own RNA-dependent-RNA-polymerase. Replication occurs later in 
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infection where vRNA is also transcribed into full length cRNA copies from 
which more copies of vRNA are made to be later on packaged into new 
virions. During transcription the subunit of PB2 recognizes and binds 
m7Gpppm-CAP structures of newly synthesized cellular mRNA. “CAP –
snatching” occurs, where the endonuclease activity of PB1 cuts off the CAP 
and attaches it to the 3’ end of vRNA initiating transcription via the 3’ OH 
end of the CAP structure. The viral mRNA acquires the missing 
polyadenylation tail by the PB1 subunit which elongates the nucleotides 
until a stretch of five to seven uridines at the 5’ end of the vRNA. The RNA 
polymerase stutters at this uridine stretch and thereby adding the poly (A) 
tail. Positive sense viral mRNAs are transported out of the nucleus into the 
cytoplasm for protein synthesis by the ribosomes. After translation the 
membrane proteins (HA, NA and M2) are transported through the rough 
endoplasmatic reticulum (rER) and the golgi apparatus to the cellular 
membrane. During transport different post translational modifications like 
N-glycolsylation or palmitoylisation occur. The neuraminic acid residues of 
NA are deleted in order to prevent premature binding to HA.  
Due to their NLS the other remaining proteins (PB2, PB1, PA, NP, M1, NS1 
and NEP) are imported back into the nucleus to assist in viral replication 
and vRNP assembly. During late stages of infection, newly synthesized 
vRNPs are transported to the cytoplasm due to the nuclear export protein 
(NEP) interacting with the cellular nuclear export machinery. The BM2 
protein of influenza B virus is synthesized in the late phase of infection 
and then incorporated into the virions as a subviral component and plays 
a critical role in production of infectious virus (Imai et al., 2008, Odagiri et 
al., 1999). Finally, progeny viruses assemble at the apical surface of the 
cell and lipid rafts and bud from the host cell plasma membrane.                   
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Fig. 2: Influenza virus replication cycle 
 
 
 
4.1.3. Structure and function of the NS1 protein 
 
The eleventh gene of the influenza virus, the NS1 protein, is a non 
structural protein, which is synthesized in the infected cell but is not 
incorporated into the progeny virus. NS1 is a dimeric, multifunctional 
protein expressed by all influenza strains.  In the case of influenza A virus 
NS1-A contains 890nt and NS1-B 1096nt coding for two mRNAs (Lamb & 
Choppin, 1979, Lamb et al., 1980). The first one encoding the NS1 protein 
of 230 amino acids (aa) or 281aa in length for influenza B viruses and the 
other mRNA derived by splicing of the NS1 mRNA, encoding the nuclear 
export protein (NEP/NS2) of 121aa in length for influenza A or 122aa for 
influenza B viruses, respectively. NEP plays a major role in exporting the 
newly synthesized vRNPs out of the nucleus. Unspliced NS1 mRNA is 
exported very efficiently out of the nucleus, ensuring presence of NS1 
protein already at early stages of infection and thereby counteracting the 
onset of the host’s antiviral immune response and ensuring prolongation 
of the viral replication cycle (Alonso-Caplen et al., 1992). 
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NS1 is a 26kDa protein involved in both protein-RNA as well as protein-
protein interactions. Each dimer consists of an N-terminal RNA-binding 
domain (RBD) and a C-terminal effector domain (ED) as shown in Fig. 3 
(Palese, 2007). Due to its NLS in each of the two domains NS1 protein 
localizes mainly in the nucleus (Greenspan et al., 1988). In the cytoplasm 
the NS1 protein is found as a result of the NES (nuclear export signal) in 
the ED (Li et al., 1998). Although there is only 20% sequence homology 
between NS1-A and NS1-B protein, the function to counteract the hosts 
own immune system and modulate and regulate the immune response at 
several stages seems to be alike.    
 
 
Fig. 3: Binding sites of cellular proteins on NS1 domains of Influenza A and B viruses 
 
One of the functions of the RBD domain of NS1-A is to prevent activation 
of the cellular Ser/Thr protein kinase R (PKR) (Bergmann et al., 2000, 
Hatada et al., 1999, Krug et al., 2003). The RBD of NS1-A sequesters 
dsRNA present in the nucleus away from PKR and/or directly binds to PKR 
by its ED and therefore prevents its autophosphorylation and activation (Li 
et al., 2006, Min et al., 2007). Activated PKR induces phosphorylation of 
its substrate the eucaryontic translation-inhibition factor (eIF-2α) leading 
to a blockage in cellular protein synthesis which would also affect viral 
protein synthesis in infected cells leading to inhibition of viral replication 
(Garcia et al., 2006). The RBD of NS1-B is also able to bind dsRNA and 
suffices to inhibit PKR activation as demonstrated in vitro (Dauber et al., 
2006).  
Furthermore, it was shown that the function of the RBD is not only to 
sequester dsRNA, a putative by-product of viral replication, away from 
PKR but also from the cytoplasmic antiviral protein 2’-5’ oligoadenylate 
 11 
synthetase (2’5’-OAS) an enzyme binding in its activated conformation to 
RNase L. Successive activation of RNase L leads to cleavage of both mRNA 
and rRNA in the cytoplasm inducing a stop in protein expression and 
hence inhibits viral replication (Silverman, 2007). Whether 2’5’-OAS is 
activated directly by interaction with the RBD or if dsRNA is sequestrated 
to prevent activation of this enzyme remains unclear.  
 
Another function of the RBD domain of NS1-A is binding to sequences in 
the 5’ untranslated regions (UTR) of viral mRNA and interacting with a 
number of cellular proteins. Thereby recruiting viral mRNA closer to the 
translation machinery to enhance selective translation of viral mRNAs over 
cellular mRNAs (Burgui et al., 2003). Thus to increase viral synthesis NS1 
was shown to bind to 5’ UTRs, poly(A) binding protein 1 (PABP1), eIF4GI, 
hStaufen to form multi-protein translation-initiation complexes (Aragon et 
al., 2000, Burgui et al., 2003). If the same is true for NS1-B has not yet 
been elucidated.  
 
NS1-B is able to inhibit conjugation of interferon stimulated gene 15 
(ISG15) to its downstream binding partners independently form RNA-
binding. ISG15 is an ubiquitin-like protein whose expression is 
transcriptionally induced by IFN-α/β (Lenschow et al., 2007, Yuan et al., 
2002, Yuan & Krug, 2001). ISG15 conjugation selectively induces the 
onset of other early interferon response genes in infected cells, a function 
which is not shared with NS1-A protein (Krug et al., 2003, Sadler & 
Williams, 2008). 
 
 
A function of the NS1-A ED is binding to the subunit of the cleavage and 
polyadenylation specificity factor (CPSF) and poly(A)-binding protein II 
(PABII) thereby inhibiting host pre-mRNA processing. CPSF is a cellular 
protein required for pre-mRNA maturation, in detail for cleavage and 
polyadenylation (Chen & Krug, 2000). Upon binding of PABII to cleaved 
mRNA and by its elongation of the poly(A) tail, CPSF joins and promotes 
further elongation of the poly(A) ensuring correct 3’end processing. The 
functional processed cellular mRNA can now be exported from the nucleus 
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(Chen & Krug, 2000). The interaction of the NS1-A ED together with 
binding to the poly(A) tails of cellular mRNAs and to NS1-I and NS1-BP 
leads to the selective inhibition of nuclear export of cellular pre mRNAs 
and the inhibition of splicing, respectively . NS1-B does not interfere with 
the mRNA processing and is not able to inhibit export of cellular mRNA 
(Wang & Krug, 1996). 
Interestingly, NS1-A is not only involved in suppressing the signaling 
events mentioned above but is also involved in promoting the 
phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway (Ehrhardt et 
al., 2007b, Hale et al., 2006, Hale & Randall, 2007, Shin et al., 2007). At 
late stages during infection NS1-A ED binds and activates PI3K. 
Regulation of this pathway induces many cellular changes that maintain 
cell survival during influenza virus replication, including anti-apoptosis, 
cell growth, proliferation and cytokine production or signalling. This is 
again a function that is unique for influenza A and is not shared by 
influenza B (Ehrhardt et al., 2007a). 
The interferon antagonistic function of NS1 was discovered first by the 
construction of an NS1 deletion virus, lacking the complete NS1 ORF 
(delNS1) (Egorov et al., 1998, Garcia-Sastre et al., 1998). It was 
discovered that this virus was severely attenuated in IFN competent 
systems such as MDCK cells and 11-day old embryonated eggs, but could 
replicate in IFN deficient systems such as Vero cells and was pathogenic in 
STAT1-/- mice (Garcia-Sastre et al., 1998). Recombinant influenza viruses 
with long C-terminal truncations in the NS1 gene also grew well in Vero 
cells, but were attenuated in growth according to the length of their 
deletions in MDCK and wild-type mice. This again demonstrates that NS1 
is dispensable in the absence of an immune response and is a viral 
accessory protein not required for viral replication (Egorov et al., 1998, 
Garcia-Sastre et al., 1998). 
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4.1.4. NS1 combating the innate immune system 
 
Various hosts counteract influenza invasion by inducing an antiviral 
response activated by their innate immune system early after infection 
(Hale et al., 2008). This response involves three major steps:  
1. Detection of viral infection and type I interferon (IFN) secretion by 
the infected cell 
2. Binding of IFNα/β to its extracellulary expressed receptors and 
transcriptional induction of IFN-stimulated genes  
3. Induction of an antiviral state of infected and neighbouring cells. 
 
The host cell recognizes influenza infection through a variety of cellular 
sensors which all trigger signalling events designed to eliminate the 
invading virus and activate the interferon system. The endosomal Toll-like 
receptors (TLRs) 3, TLR7 and TLR8 recognize single-stranded RNA and 
double-stranded RNA, believed to be an intermediate product during viral 
replication. The cytosolic RNA helicase retinoic acid-inducible gene I (RIG-
I) gets activated upon recognition of cytoplasmic influenza-virus-derived 
ssRNA bearing 5’ triphosphates. Both endosomal and cytosolic sensors 
start a signalling cascade leading to the transcription of the IFNα/β 
promoter in the nucleus (Fernandez-Sesma, 2007).  
The pattern recognition receptors TLR activate the adaptor molecules 
MyD88 and lead to further signalling over Toll/IL-R domain-containing 
adaptor-inducing IFN factor (TRIF) and finally to activation of the IκB 
kinase-ε (IKKε) and subsequently the interferon response factors (IRFs) 
and induction of a proinflammatory response (Aderem & Ulevitch, 2000).  
The cytosolic RIG-I contains three functional domains, the caspase-
recruiting domain (CARD)-like domain responsible for downstream 
signalling, the helicase domain binding to 5’-triphosphate RNA and finally 
the repressor domain regulating the activation of RIG-I and only allowing 
subsequent association with downstream adaptors in the presence of an 
adequate stimulus like viral RNA (Hornung et al., 2006, Opitz et al., 2007, 
Pichlmair et al., 2006, Yoneyama et al., 2004). RIG-I is able to 
discriminate between foreign and endogenous ssRNA via the exposed 5’-
3p as during influenza virus replication (Pichlmair et al., 2006). Cellular 
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mRNA is masked by a 7-methyl-guanosine cap and therefore not 
recognized by RIG-I. Although the vRNA genome of influenza virus is 
covered by the NP protein and bound by the vRNP complex, its 
triphosphate RNA at the 5’ end is detected by RIG-I helicase domain and 
causes a conformational change leading to its activation (Yoneyama et al., 
2004). The dogma that dsRNA is the main marker of infection which is 
common to all viruses and that this dsRNA is the reason for triggering the 
signalling events leading to an antiviral response is challenged by the 
ability of RIG-I to recognize specific residues independent of single or 
double strandedness. Once RIG-I is activated it interacts with a 
homologous CARD-like domain of the adaptor molecule MAVS (also known 
as IPS-1, VISA or Cardif) triggering a signalling cascade resulting in the 
activation of the kinases Traf family-member-associated NF-κB activator – 
binding kinase 1 (TBK-1) and IκB kinase-ε (IKKε) and thereupon C-
terminal phosphorylation of the serine residues of the interferon regulation 
factor 3 (IRF-3) and IRF-7 (Fitzgerald et al., 2003, Kawai et al., 2005, 
McWhirter et al., 2004, Meylan et al., 2005, Seth et al., 2005, Sharma et 
al., 2003, Xu et al., 2005). This provokes a conformational change leading 
to the translocation and accumulation of activated IRF to the nucleus. 
Once IRF is present in the nucleus, it associates with the nuclear co-
activator CBP/p300, the nuclear factor κB (NFκB) and ATF2/c-Jun to 
induce transcription of the IFNα/β genes (Fig.6) (Du & Maniatis, 1992, 
Juang et al., 1998, Lin et al., 1998, Peters et al., 2002, Sato et al., 2000, 
Wathelet et al., 1998, Weaver et al., 1998).  
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Fig.6. Activation of RIG-I by viral RNA (Randall & Goodbourn, 2008).  
 
NS1 protein of influenza virus has not only the ability to directly interact 
and bind RIG-I and thus prevent RIG-I mediated production of IFNα/β 
mRNA, but also the ability to prevent export of mature IFN mRNA from 
the nucleus by inhibiting posttranscriptional processing of cellular mRNA 
(Mibayashi et al., 2007, Pichlmair et al., 2006). This is achieved as 
mentioned before by binding of NS1 to CPSF and PABII. Furthermore it 
could be shown that the NS1-A and NS1-B protein inhibit phosphorylation 
and nuclear translocation of IRF-3 (Talon et al., 2000a). This strategy by 
influenza virus ensures the prevention of cellular production of antiviral 
proteins and thus allowing continuous viral replication. 
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Fig.7. Signalling pathway activated by IFN-α/β (Randall & Goodbourn, 2008). 
 
The produced IFNα/β proteins are secreted from the infected cell and bind 
to the IFN receptor on the cell surface establishing an antiviral state in the 
neighbouring uninfected cell and thus preventing viral spread (Fig.7). 
Upon binding of IFN to the receptor, two Janus protein tyrosine kinases 
(Jaks), namely Jak1 and Tyk1 get oligomerized and cross activated. They 
get autophosphorylated and lead to further phosporylation of the signal 
transducers and activators of transcription (STAT) family. STAT1 and 
STAT2 form the interferon stimulated gene factor 3 (ISGF-3) transcription 
complex, which translocates to the nucleus and mediates activation of the 
transcription of all ISRE controlled genes (Randall & Goodbourn, 2008). 
The interferon stimulated response element is responsible for the 
expression of more than 300 interferon-stimulated genes, encoding 
proteins that have antiviral, antiproliferative or immunomodulatory 
activities. The antiviral actions are mediated by several ISG proteins like 
MxA protein, ISG-15, -54, -56, 2’5’OAS and PKR (Decker et al., 2002, 
Garcia-Sastre & Biron, 2006, Holzinger et al., 2007, Samuel, 2001). Mx 
proteins belong to the family of dynamin like guanosine triphosphates 
(GTPases). The Mx proteins were originally identified as factors conferring 
resistance to lethal influenza A infection in mice. The human MxA 
accumulates in the cytoplasm and inhibits viral replication. It was shown 
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that MxA is selectively induced by type I IFNs but not directly by virus 
infection (Holzinger et al., 2007). The antiviral mechanism against 
influenza virus infection remains yet to be defined. However, with other 
RNA viruses, MxA forms complexes with the nucleocapsids of the viruses 
which are then degraded. As described previously, PKR detects foreign 
dsRNA in the cytoplasm, leads to inhibition of eIF-2α associated with 
blocking the translation initiation, whereas 2’5’-OAS, also detecting 
foreign dsRNA in the cytoplasm, activates RNase L leading to degradation 
of mRNA (Levy & Garcia-Sastre, 2001). NS1 is interfering with both ISGs, 
in the case of PKR it is directly binding whereas in the case of 2’5’-OAS, 
NS1 is sequestering dsRNA in the nucleus. For MxA there has been no 
evidence of interaction with NS1. 
The establishment of an antiviral state is associated with the secretion of 
such pro-inflammatory cytokines and chemokines as interleukin-6 (IL-6), 
tumor necrosis factor alpha (TNF-α), IL18, CCL3, CCL4, CCL5 (RANTES), 
IFN-γ and many more, thereby linking the innate to the adaptive immune 
response (Julkunen et al., 2001, Kaufmann et al., 2001, Matikainen et al., 
2000). 
 
4.1.5. NS1 circumventing the adaptive immune system 
 
After naturally occurring influenza virus infection, the development of a 
cellular and humoral immune response takes place. Sentinel dendritic cells 
(DCs) detect an influenza virus infection and upon stimulation start to 
mature, release proinflammatory cytokines and chemokines and migrate 
to the lymph nodes. The antigen is then presented to cytotoxic and helper 
T-cells initiating the adaptive immune response (Hale et al., 2008). 
Clearance of infection is mediated by cellular immunity involving a T-
helper 1 (Th1) response. The optimal Th1 immunity consists of virus 
specific IFN-γ-secreting CD4 and CD8 T cells recruited to the site of 
infection that lyse infected cells. Cytokines and chemokines as a part of 
innate immunity favor the development of antiviral and Th1 type immune 
responses affecting the adaptive immune response. The NS1 protein of 
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influenza virus was shown to prevent the induction of several genes 
involved in DC maturation and migration (Fernandez-Sesma et al., 2006). 
 
Protection against re-infection relies on neutralizing antibodies mainly 
against the glycoproteins HA and NA. Influenza virus developed 
mechanisms to avoid recognition by preexisting neutralizing antibodies, a 
process termed antigenic shift and antigenic drift giving rise to new 
epidemics and pandemics in humans. Antigenic drift is the accumulation of 
changes in the antigenic sites of the HA and NA gene due to the high 
mutation rate of RNA viruses. Additionally, antigenic shift is the capture of 
novel HA or NA genes by exchange of genes with another virus during 
reassortment (Palese, 2007).  
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4.2. Reverse genetics for influenza viruses  
 
Orthomyxoviruses are negative strand RNA viruses rendering their 
genome un-infectious and resulting in no formation of viral replication 
when introduced into cells. This is in contrast to positive strand RNA 
viruses where the RNA resembles mRNA and is itself already infectious. 
 
4.2.1. RNP-transfection 
 
In the case of influenza viruses RNP complexes represent the smallest 
infectious entity required for encapsidation, transcription and replication of 
the viral genome, therefore initial experiments focused on reconstituting a 
functional RNP complex in vitro giving rise to the genetic engineering of 
the influenza virus genome.  
In these RNP transfection experiments cDNA for a specific viral segment 
was synthesized and mixed with purified NP and polymerase complex 
proteins which were eventually transfected into the cell and super-infected 
with a helper virus to provide the remaining viral segments (Luytjes et al., 
1989). During replication of the helper virus the transfected RNPs were 
replicated and assembled into new virions. In order to distinguish between 
helper virus and novel rescued virus a selection pressure has to be applied 
displaying a huge disadvantage for this system.  
 
4.2.2. Plasmid-only transfection 
 
The generation of influenza viruses entirely from cloned cDNA a decade 
after the first reverse genetic approach, demonstrated a powerful 
alternative to the cumbersome limitation of early helper virus infection 
experiments (Fodor et al., 1999, Hoffmann et al., 2002, Neumann et al., 
1999). Each of the eight viral segments was cloned in negative orientation 
in plasmids containing a human RNA polymerase I promoter on the one 
side and the hepatitis delta virus ribozyme on the other end in order to 
ensure that RNA processing gave the correct 3’ end of the vRNA (pPolI 
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plasmid). Transfection of the eight pPolI plasmids together with the four 
RNA polymerase II-driven plasmids (pPolII) encoding the NP and the three 
viral polymerases (PB1, PB2 and PA) into Vero (African green monkey 
kidney) cells or 293T cells resulted in recovery of infectious influenza 
virus. Later on, co-cultures of the human 293T cells, which can be 
efficiently transfected due to possession of the human RNA polymerase I, 
and the canine MDCK (Madin–Darby canine kidney) cells, which support 
high growth of influenza virus, were transfected. 
Further improvements simplifying the genetic engineering of influenza 
virus involved the simultaneous transcription of vRNA and mRNA from one 
plasmid requiring the transfection of only 8 plasmids (Fig.8.). The 
bidirectional plasmids contain two promoter and termination sites, the 
viral cDNA is flanked by a human RNA-polymerase I promoter and murine 
RNA polymerase I terminator as well as a RNA polymerase II promoter 
and polyadenylation signal. After transfection the cellular RNA polymerase 
I is responsible for generating vRNA from the plasmid cDNA and 
transcription by the cellular RNA polymerase II resulted in an mRNA 
transcript leading to translation by the cellular ribozymes and 
accumulation of viral proteins. Successively the viral proteins and vRNAs 
were assembled in the transfected cell and the virus budds from the cell 
membrane (Hoffmann et al., 2000). 
Since cell lines appropriate for human vaccine production (Vero cells) 
could so far not be transfected with high efficiencies thereby limiting their 
use in reverse genetics systems. To address this limitation, a reverse 
genetic system was established reducing the number of plasmids required 
for virus production (Neumann et al., 2005). The eight pPOLI transcription 
plasmids for viral RNA synthesis are combined on one plasmid and 
similarly the polII transcription cassettes for the polymerase complex were 
combined. By this the number of the required plasmids was significantly 
reduced and influenza virus could be produced more efficiently in Vero 
cells than with the previous 12 or 8 plasmid system.  
These advances in genetic engineering of influenza virus benefited a 
better understanding of the structure or function of different influenza 
virus proteins. Due to the achievements in reverse genetics it is possible 
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to study the impact of mutations introduced into the cDNA of specific 
genes, to examine the interaction of viral and cellular proteins or the 
impact they have on pathogenicity. Plasmid only rescue systems have 
been described for all three influenza viruses (A, B and C). Furthermore 
chimeric viruses were rescued in an influenza A background expressing HA 
and NA proteins from influenza B virus demonstrating that the HA and NA 
on influenza A can be functionally replaced with the glycoproteins from 
influenza B (Flandorfer et al., 2003). Reverse genetics experiments also 
helped to understand the extraordinary virulence of the extinct 1918 
pandemic influenza A virus by cloning all 8 genes and subsequent rescue 
of this virus (Tumpey et al., 2005). 
Hereafter, reverse genetics will be a powerful and fast tool to design novel 
and improved influenza live attenuated vaccine candidates for epidemic 
and pandemic use. 
 
 
Fig. 8: Reverse Genetics system after (Hoffmann et al., 2002) adapted partly from B. 
Dauber  
RNA-Pol I: RNA-polymerase I; RNA-Pol II: RNA-polymerase II; PI: humane RNA-Pol I-
promoter; tI: murine terminator; PIICMV: cytomegaly virus RNA-Pol II-promotor; aIIBGH: 
polyadenylation signal of the bovine growth hormone gene 
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4.3. Vaccine development 
 
As viral growth in embryonated hens’ eggs was discovered in the 1930ies, 
the US military developed the first approved inactivated vaccine for 
influenza virus in the 1940s and since then a lot has been done to 
increase safety and efficacy (Hilleman, 2002). To date there are two 
different approaches licensed, the trivalent inactivated vaccine (TIV) and 
the trivalent live attenuated influenza virus vaccine (LAIV) (Fig.8). Despite 
the efficacy of both there is still a need for further development. Not only 
is the price per dose, the speed and ease of production limiting, but also 
the cross-protection against variant strains or the choice of the substrate 
to grow the virus in and the efficacy in immunologically naïve or 
compromised populations remain critical issues. 
 
4.3.1. Inactivated vaccine (TIV) 
 
There are three types of inactivated vaccines: whole virus, split-product or 
subvirion and surface-antigen. Nearly all inactivated vaccines are split-
product (produced form highly purified influenza virus) or surface antigen 
vaccines (containing only purified HA and NA glycoproteins). Whole virus 
vaccine was shown to elicit adverse reactions, especially in children.  Due 
to antigenic drift of the virus, caused by point mutations in the surface 
antigens, the vaccine formulation is changed almost annually. However, it 
always consists of three components, influenza A H1N1, H3N2 and 
influenza B. For preparation of the TIV, the viral reassortants are 
propagated in embryonated chicken eggs, subsequently UV-inactivated, β-
propiolacton or formaldehyde-inactivated and after purification chemically 
disrupted. Not only can residual amounts of egg proteins remain in the 
formulation causing problems for allergic populations, but most of all this 
process is time-consuming, cost-intensive and relies on the availability 
and supply of SPF (specific pathogen-free) embryonated chicken eggs 
which could cause problems during a pandemic (Palese, 2006). 
The effectiveness of the current TIV depends on the “antigenic match” 
between novel circulating virus and viral strains used for the vaccination, 
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the age and the immune status of the vaccinated population. The TIV is 
injected intramuscularly eliciting a high mean serum IgG antibody 
response and show a 70-90% efficacy in preventing illness in the healthy 
population whereas decreased efficacy of only 30-60% in the young and 
elderly (Cox et al., 2004).  However, if efficacy is determined by 
prevention of death, than 80% of the young and elderly are protected 
(Nichol et al., 1994, Nichol et al., 1998). Therefore improvements are 
needed to boost the immune system and to reduce the amount of antigen 
needed, such as formulation with adjuvants. To date most of the TIVs do 
not contain an adjuvant. Several have already been licensed like Alum and 
Mf59 oil-in-water emulsion for conventional influenza vaccines. A huge 
supply problem would be met, if under adjuvant conditions the dose of 
antigen currently present per vaccine (45µg of HA) could be significantly 
reduced and still stimulate an adequate immune response. Researchers 
are now investigating liposome-like preparations containing cholesterol 
and viral particles as immuno- stimulating complexes (ISCOM) and could 
demonstrate their efficacy even by nasal administration in mice 
(Sambhara et al., 2001). However, no protection was observed in a 
macaque model against distant influenza drift variants (Rimmelzwaan et 
al., 2001). Preparations of liposomal-like complexes (INFLUSOME-VAC) 
admixed with liposomal human Interleukin-2 (IL-2), to stimulate a better 
cross-reactivity, appear to be both safe and more immunogenic than the 
currently used vaccine in the elderly (Ben-Yehuda et al., 2003). Another 
approach is the use of the heat-labile Escherichia coli toxin complexed 
with lecithin vesicles together with TIV for intranasal administration 
(Glueck, 2001). Further research has to be done in order to make this 
approach safer, for this specific adjuvant was shown to be associated with 
Bell’s palsy disease. Other attempts include synthetic adjuvants such as 
synthetic lipid A, muramyl peptide derivates, cationic molecules and poly 
I:C (Ichinohe et al., 2005). Virosomes consisting only of reconstituted 
viral envelopes and completely lacking RNA have also been shown to be 
effective alternate approaches for influenza vaccines (Huckriede et al., 
2005).   
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4.3.2. Live vaccines 
4.3.2.1. Live cold-adapted vaccine (LAIV) 
 
LAIVs are administered intranasally displaying a huge advantage over TIV. 
Cold-adapted influenza vaccine was used in Russia already for decades, 
was shown to be protective in children and demonstrated no side effects. 
Furthermore as it is always the concern of live vaccines, no sign of spread 
or virulent revertants could be found (Wareing et al., 2001). Recently it 
was also licensed in the US as Flumist by MedImmune (Vesikari et al., 
2006b). In order to generate attenuated cold-adapted strains the 
influenza virus isolate was passaged in embryonated eggs or primary 
chicken kidney cells several times to adapt them to growth at low 
temperature of 25°C (Herlocher et al., 1993). The resulting master strain 
is temperature sensitive (ts) and cold-adapted (ca) bearing several point 
mutations restricting growth at high temperatures as 37°C. Thereby 
exhibiting a strong attenuated phenotype in animals as well as humans 
replicating only in the upper respiratory tract in which temperatures do 
not exceed 32-33°C. The three NA and HA proteins of the current 
epidemic strains are semi-annually introduced by genetic reassortment. 
The resulting 6:2 reassortants contain 6 non-surface proteins of the 
master strain and the HA and NA from circulating A and B viruses 
according to the WHO recommendations.                   
LAIV elicits a local IgA mucosal antibody response in the upper respiratory 
tract, lower but nevertheless detectable serum IgG antibody titers than 
TIV and a longer lasting virus specific T cell response suggesting that this 
vaccine may provide better cross-protection against antigenic drift 
variants.  The protection however is better in certain age groups from 6 
months to 9 year old children, nevertheless resulting in an overall efficacy 
of 73-96% in a population of 6 months to 18 years (Vesikari et al., 
2006a). Additional advantages besides the nasal application poses the 
development of reverse genetics making it possible to generate the 6:2 
reassortants much faster than by classical reassortment and furthermore 
abolish the presence of adventitious agents in the vaccine preparation. 
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4.3.2.2. Live recombinant vaccine  
 
Since the development of genetic engineering accompanied by its 
possibility to alter every single gene in the influenza virus, new vaccine 
approaches can be considered. So far none of them has been yet licensed 
but attempts and improvements have been made by several groups. It is 
possible to tailor made strains with specific properties leading to their 
attenuation.   
One attempt was the exchange of promoter regions of the NA protein of 
influenza A and B viruses, which led to attenuation in mice (Muster et al., 
1991). Another group introduced mutations by site-directed mutagenesis 
into the PB2 gene leading to temperature-sensitive (ts) and attenuated 
phenotype in mice and ferrets (Murphy et al., 1997, Parkin et al., 1997). 
Another attenuation mechanism was met by the generation of a virus 
lacking the nuclear export (NS2/NEP) protein. These virus particles 
undergo just a single round of replication, expressing the viral proteins 
but due to the missing NS2/NEP protein no infectious viral particles are 
formed (Watanabe et al., 2002b). Elimination of the M2 gene renders a 
virus to grow efficiently in tissue culture but poorly in mice, a prerequisite 
for a potential live virus vaccine candidate (Watanabe et al., 2002a). 
Production of such viruses in tissue culture can be achieved by the use of 
complementing cell lines expressing the missing protein. Additionally 
virus-like-particles (VLPs) have been shown to generate a mucosal 
immune response when applied to a mucosal surface especially in 
combination with an adjuvant. VLPs consist of influenza virus structural 
proteins like HA, NA, M1 and M2 which are sufficient for assembly and 
budding from the cell membrane. On this basis it is possible to produce a 
vaccine in large quantities due to the usage of Sf9 insect cells. 
Furthermore VLPs demonstrated to be effective in an animal model, 
however the data of clinical trials are so far not available (Galarza et al., 
2005).  
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4.3.2.3. NS1 live-attenuated vaccine 
 
Finally, one approach comes from the finding that the non-structural 
protein (NS1) has IFN antagonistic properties (Egorov et al., 1998, Garcia-
Sastre et al., 1998). Influenza viruses lacking NS1 are not able to 
counteract the host immune response and therefore type I IFN production 
is induced and viral replication is blocked. Truncations in the NS1 protein 
of influenza A and B viruses were shown to result in an altered phenotype 
with different virulence characteristics in mice (Hai et al., 2008, Talon et 
al., 2000b). The level of attenuation directly correlated with the length of 
the NS1 protein (Baskin et al., 2007, Ferko et al., 2004, Hai et al., 2008, 
Quinlivan et al., 2005, Richt et al., 2006, Solorzano et al., 2005). 
Therefore an optimal balance between efficacy and safety has to be met, 
retaining the virus’ replication deficiency and inducing significant amounts 
of IFN which cannot be overcome by the virus. Due to the fact that viruses 
with an impaired NS1 protein induce higher levels of IFN than 
corresponding wild-type viruses, the produced IFN enhances the 
production of primary antibodies and contributes to the activation of 
antigen presenting dendritic cells (Stasakova et al., 2005). Thus the 
immune response to NS1 truncated viruses might be enhanced and 
demonstrate increased efficacy when compared to conventional TIV or 
LAIV. Moreover IFN acts as an additional self-adjuvant (Ferko et al., 2004, 
Le Bon et al., 2001).  
These IFN-sensitive vaccine candidates require tissue culture cell lines 
that are not able to produce and respond to IFN after influenza virus 
infection. Therefore Vero cells are one cell line of choice, as they do not 
produce IFN due to a natural deletion of the IFN genes (Desmyter et al., 
1968, Mosca & Pitha, 1986)  and furthermore they pose the advantage 
that they are a certified cell line suitable for vaccine production promoting 
the growth of viruses with an impaired NS1 function equally to wild type. 
The overall benefits of these live influenza vaccine candidates with 
impaired NS1 protein over TIV are the replication-deficient phenotype, the 
intranasally administration, the presumable efficacy in immunologically 
naïve populations, the triggering of a mucosal immunity, the lack of 
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adventitious agents and the production in large quantities due to tissue 
culture production.  
 
 
4.3.3. DNA vaccination  
 
Another approach very distinguished from TIV and LAIV is DNA 
vaccination. DNA vaccines consist of Escherichia coli derived plasmid DNA 
encoding one or more influenza proteins of interest. The immune response 
is only directed against the inserted protein not the vector itself. A DNA 
vaccine expressing HA protein was shown to be effective in mice, ferrets 
and chicken when injected intramuscularly or given with a bio ballistic 
gene gun(Donnelly et al., 1995, Kodihalli et al., 2000, Webster et al., 
1994). With this vaccination method, both a humoral and cell-mediated 
immune response is induced, due to the expression of the antigens in situ. 
The great potential of this technology is the speed of vaccine generation, 
the ease of production and its low cost. Despite the drawback that 
experiments so far were limited to animal models, efforts invested into the 
development of a universal approach inducing protective humoral and cell 
mediated immunity to a variety of antigens seem worthwhile. 
 
Fig. 8: Table of influenza virus candidates 
IM: intra muscular; IN: intranasal; AB: antibody; adapted from Kawaoka et al. 
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5. Objective of thesis 
 
The aim of the thesis was to develop a reverse genetic system for the 
generation of contemporary influenza B viruses encoding C-terminally 
truncated NS1 proteins or completely lacking the ORF of NS1. Rescued 
viruses were selected for high growth on Vero cells. The efficacy and 
immunogenicity in animals was demonstrated and their potential for the 
use as vaccine candidates in a trivalent live-attenuated vaccine 
formulation was assessed. 
 
The thesis is a collection of results outlined in 2 chapters, a published 
paper in chapter 6 and a manuscript submitted for publication in chapter 
7. 
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6. Influenza B mutant viruses with truncated NS1 
proteins grow efficiently in Vero cells and are 
immunogenic in mice  
 
 N. Wressnigg, A. P. Shurygina, T. Wolff, M. Redlberger-Fritz, T. 
 Popow-Kraupp, T. Muster, A. Egorov and C. Kittel 
 J Gen Virol 2009, Feb; 90: 366 - 374 
 
 
6.1. SUMMARY 
 
We generated contemporary influenza B viral strains encoding carboxy-
terminally truncated NS1 proteins. Viable viruses containing the amino-
terminal 14, 38, 57 or 80 amino acids of the NS1 protein were rescued on 
Vero cells. The influenza B NS1 truncation mutants are impaired in their 
ability to counteract interferon production, induce antiviral pro-
inflammatory cytokines early after infection and show attenuated or 
restricted growth in interferon-competent hosts. In Vero cells all obtained 
viruses replicate to high titers comparable to the influenza B wild-type 
virus. Mice, which received a single, intranasal immunization of the NS1 
truncation mutants elicit antibody response and protection against wild-
type virus challenge. Therefore, these NS1 truncation mutants should 
prove useful as potential candidates for live attenuated influenza vaccines. 
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6.2. INTRODUCTION 
 
Influenza viruses belong to the Orthomyxoviridae family and are 
enveloped, negative-sense RNA viruses with a segmented, single-stranded 
genome (Wright, 2001). Whereas influenza A virus has a broad host 
reservoir in many avian and mammalian species, influenza B virus is 
thought to be almost exclusively restricted to humans (Wright, 2001). 
Most of the proteins expressed by influenza A and B viruses are believed 
to have similar functions despite the biological and epidemiological 
differences between these two viruses. Clear exceptions are the pro-
apoptotic PB1-F2 protein uniquely found in most influenza A virus strains 
(Chen et al., 2001) and the NB protein solely expressed by influenza B, 
which contributes to virulence (Imai et al., 2008, Shaw et al., 1983).  
Various hosts counteract viral invasion by inducing an antiviral response 
activated by their innate immune system. This response involves three 
major steps: (a) detection of viral infection and type I interferon (IFN) 
secretion by the infected cell, (b) binding of IFN to its extracellulary 
expressed receptors and transcriptional induction of IFN-stimulated genes 
leading to (c) the  induction of an “antiviral state” of infected and 
neighboring cells. In detail, the activation of the host-type I IFN system is 
mediated predominantly upon recognition of influenza-virus-derived RNA 
bearing 5’ triphosphates by the cytoplasmatic RNA helicases RIG-I  
(Pichlmair et al., 2006, Yoneyama et al., 2004). Interaction of RIG-I with 
MAVS (also known as IPS-1, VISA or Cardif) triggers a signaling cascade 
resulting in the activation of the kinases TBK-1 (Traf family-member-
associated NF-κB activator – binding kinase 1), IKKε (IκB kinase-ε) and 
thereupon phosphorylation of the transcription factor IRF-3 (interferon 
regulating factor 3)  (Fitzgerald et al., 2003, Kawai et al., 2005, McWhirter 
et al., 2004, Meylan et al., 2005, Seth et al., 2005, Sharma et al., 2003, 
Xu et al., 2005). Activated IRF-3 translocates and accumulates in the 
nucleus. Together with the nuclear coactivator CBP/p300, NFκB (nuclear 
factor κB) and ATF2/c-Jun (activating transcription factor 2) induce 
transcription of IFN-α/β (Du & Maniatis, 1992, Juang et al., 1998, Lin et 
al., 1998, Peters et al., 2002, Sato et al., 2000, Wathelet et al., 1998, 
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Weaver et al., 1998, Yoneyama et al., 1998). IFN-α/β are secreted from 
the infected cell and bind to the IFN receptor on the cell surface. This 
triggers a signal cascade through the JAK/STAT pathway leading to the 
formation of the ISGF-3 (Interferon stimulated gene factor 3) transcription 
complex, which, in turn is responsible for the expression of more than 100 
interferon-stimulated genes, some of them associated with antiviral 
activity, e.g. Mx proteins, ISG-15, -54, -56, 2’,5’OAS (2’,5’- oligo (A) 
synthetase) and PKR (Protein kinase R) (Garcia-Sastre & Biron, 2006, 
Holzinger et al., 2007, Samuel, 2001). This establishment of an antiviral 
state is associated with the secretion of such pro-inflammatory cytokines 
and chemokines as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-
α), IL-18, CCL3, CCL4, CCL5 (RANTES), IFN-γ and many more (Julkunen 
et al., 2001, Kaufmann et al., 2001, Matikainen et al., 2000).  
During its evolution, viruses have developed a mechanism to overcome 
this defense strategy of the innate immune system. Earlier on, it could be 
demonstrated that the non-structural protein 1 (A/NS1) plays this role for 
influenza A viruses by antagonizing the IFN response of the infected cell 
(Egorov et al., 1998). In detail, A/NS1 has been associated with a number 
of regulatory functions during virus infection: (a) inhibition of host mRNA 
polyadenylation and pre-mRNA splicing, which contributes to the virus-
induced shutoff of host protein synthesis (Lu et al., 1994, Nemeroff et al., 
1998), (b) binding to the poly(A) tails of mRNAs, thus inhibiting their 
nuclear export (Qiu & Krug, 1994), (c) regulation of viral RNA polymerase 
activity (Marion et al., 1997, Shimizu et al., 1994), (d) interaction with the 
subunit of the cleavage and polyadenylation specificity factor (CPSF), 
poly(A)-binding protein II (PABII) and NS1-BP, leading to the selective 
inhibition of nuclear export of cellular mRNAs and the inhibition of splicing, 
respectively (Nemeroff et al., 1998, Wolff et al., 1996, Wolff et al., 1998), 
(e) blocking the activation of such transcription factors as IRF-3, IRF-7, 
NFκB and ATF-2/c-Jun thereby inhibiting the induction of IFN-α/β (Levy et 
al., 2002, Ludwig et al., 2006, Ludwig et al., 2002, Talon et al., 2000a, 
Wang et al., 2000), (f) sequestration of dsRNA, preventing activation of 
the IFN cascade and, finally, (g) binding to Mx protein, 2’,5’-OAS and PKR, 
the latter being one of the major antiviral proteins responsible for 
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inhibiting translational expression of cellular proteins (Dittmann et al., 
2008, Lu et al., 1995, Min & Krug, 2006, Samuel, 2001).  
Although the influenza B virus NS1 protein (B/NS1) only has about 20% 
sequence homology with A/NS1, many of the functions are shared by 
B/NS1 with some distinct exceptions. Differently to influenza A virus, no 
NS1-mediated nuclear retention of mRNAs could be observed during 
influenza B infection (Wang & Krug, 1996). Only influenza B/NS1 inhibits 
conjugation of ISG15 protein to its downstream binding partners  and 
selectively induces the onset of early response genes in such infected cells 
as ISG56 (Lenschow et al., 2007, Yuan et al., 2002, Yuan & Krug, 2001), 
a function which is not shared with influenza A viruses (Kim et al., 2002, 
Talon et al., 2000b, Wang & Krug, 1996). The N-terminal RNA-binding 
domain (RBD) of influenza B/NS1 suffices to inhibit PKR activation and has 
IFN antagonist potential (Donelan et al., 2004). In the context of a 
recombinant virus the C-terminal part of B/NS1 is required to inhibit IFN-
α/β induction in epithelial cells (Dauber et al., 2006). Some other 
functions of NS1 are common to both influenza types, e.g. binding to RNA 
via an N-terminal RBD.  
It was shown that influenza A viruses lacking a functional NS1 protein 
(∆NS1) were attenuated in such IFN-competent hosts as MDCK cells and 
wild-type (wt) mice, but replicated in IFN-deficient Vero cells and STAT1- 
(signal transducer and activator of transcription 1) or PKR knock-out (ko) 
mice (Egorov et al., 1998, Garcia-Sastre et al., 1998, Palese et al., 1999). 
Despite replication deficiency in normal hosts, animals immunized with 
∆NS1 viruses elicit a strong immune response demonstrated by increased 
antibody titers, elevated cytokine expression, activation of T-helper cells 
and protection against wt virus challenge (Donelan et al., 2003, Ferko et 
al., 2004, Talon et al., 2000b).  
Using a reverse genetic system in Vero cells, we describe the construction 
and properties of isogenic influenza B mutant viruses encoding carboxy-
terminal truncated NS1 proteins differing in length from 80 to 14 amino 
acids (aa). Analogous to the data found for influenza A NS1 mutants 
(Egorov et al., 1998), these viruses are attenuated in IFN-competent 
hosts but replicate to high titers in Vero cells. All constructed mutants are 
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able to induce antibody immune response upon intranasal (i.n.) 
immunization of mice and protected animals after homologous influenza 
virus challenge. 
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6.3. MATERIALS & METHODS 
 
6.3.1. Cells, viruses and viral infections 
 
Vero cells (ATCC CCL-81) were used for transfection experiments, for 
propagating viruses and virus titrations. Vero cells were adapted to and 
cultivated in serum-free OptiPro media (Invitrogen) with 4mM L-glutamin 
(Gibco). A549 cells (ATCC CCL-185) were cultivated in Dulbecco-modified 
Eagle medium (DMEM; Gibco) and used for growth curves of rescued 
viruses. Immortalized PKR knock out (ko) mouse embryonic fibroblasts 
(MEF) were obtained from H. Unger (University of Veterinary Medicine, 
Vienna, Austria), cultivated in Minimal Essential Medium (MEM; Gibco) 
with 10% fetal calf serum (FCS; Gibco) and used for growth curves of 
rescued viruses. Primary human nasal epithelial cells (HNEC) (Provitro) 
were cultivated in Airway Epithelial Cells Growth Medium (Provitro). 
Influenza virus B/Vienna/33/06 (B/Malaysia/2506/04-like) was provided 
by M. Redlberger (Institute of Virology, Vienna, Austria). Influenza 
B/Thüringen/02/06 (B/Jiangsu/10/03-like) virus was obtained from B. 
Schweiger (German National Reference Center for Influenza; Robert Koch 
Institute, Berlin, Germany). Both viruses were adapted to grow on serum-
free Vero cells. For determination of viral replication, indicated cells were 
washed with phosphate-buffered saline (PBS) and incubated with virus at 
the indicated multiplicities of infection (MOI) at room temperature for 30 
min. Inoculum was removed, serum-free OptiPro media containing 5µg/ml 
Trypsin (Sigma) and 250µg/ml Amphotericin B (Brystol Meyers) was 
added and cells were incubated at 33°C and 5% CO2. After indicated time 
points, supernatant of infected cells was analyzed for viral titer by TCID50 
and viral titers were calculated.  
For the measurement of IFN and cytokines on HNEC, cells were infected at 
an MOI of 2. After 30 min of incubation, inoculum was removed, 1ml of 
fresh culture medium was added and cells were incubated at 33°C and 5% 
CO2. Cell culture supernatants were harvested 24h post infection (p.i.) 
and analyzed for the presence of IFN-β, TNF-α, IL-1β and IL-6. 
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6.3.2. Generation of NS1-truncated viruses 
 
HA and NA genes of B/Thüringen/02/06 virus and the remaining 6 genes 
of the B/Vienna/33/06 master strain including non-coding regions were 
sequenced and each cloned into a phW2006 vector, a synthetically 
produced vector similar to pHW2000 (Hoffmann et al., 2002). It contains 
a PolI and PolII promoter and terminator for the bicistronic expression of 
influenza genes. The NS gene was modified by site-directed mutagenesis 
(Stratagene) to express an NS1 protein of 14, 38, 57 or 80 aa, 
respectively. Translation was terminated by two consecutive in-frame stop 
codons. The cDNA downstream of the stop codon cassette up to the 
splicing signal of NS2/NEP (position 634nt) was deleted by inverse PCR. A 
mutation at nt position 280 (A-G) in the M gene resulting in a change at 
amino acid position 86 (M-V) of the M1 protein was introduced by similar 
way. Reassortants having HA and NA genes from B/Thüringen/02/06 and 
all other genes from B/Vienna/33/06 (6:2 composition) were rescued by 
transfection of Vero cells as described previously (Kittel et al., 2005). This 
6:2 constellation was chosen because wt isolates containing all 8 genes 
from B/Vienna/33/06 lack replication in mice. Viruses were named 
according to the size of the NS1 protein, i.e. NS1-14, NS1-38, NS1-57, 
NS1-80 and NS1-wt, respectively. The expected sequences of HA, NA and 
NS genes of rescued viruses were confirmed by sequencing and for NS 
additionally by analysis of amplified RT-PCR products. All sequences are 
available upon request. 
 36 
 
6.3.3. Isolation, generation and infection of immature monocyte-
derived macrophages 
 
Peripheral blood monocytes (PBMCs) obtained from leukocyte-rich buffy 
coats of healthy donors were purified by standard gradient centrifugation 
with Ficol-Paque (GE HealthCare). The CD14-positive cells were separated 
by immunomagnetic sorting using VARIOMACS technique (Miltenyi 
BiotecGmbH) according to the manufacturer’s procedure. Isolated CD14-
cells were cultured in polystyrene 6-well plates with hydrophobic surface 
(Greiner bio-one). 2 x 106 cells per well were cultivated in 2ml RPMI 1640 
medium (Invitrogen) containing 10% FCS (Hy Clone) at 37°C in a 
humidified 5% CO2 atmosphere in the presence of 250 U/ml recombinant 
human granulocyte-macrophage colony stimulating factor (Berlex) for 7 
days. Every second day, cells were fed with 1ml RPMI-1640 medium 
containing 10% FCS. At day 7, 1 x 106 macrophages were collected and 
transferred to polystyrene tubes (Falcon), washed with serum-free 
medium and infected with the viruses described above at an MOI of 2. 
After incubation for 30 min, cells were spun down and resuspended in 1ml 
RPMI-1640 medium (Gibco) containing 10% FCS and incubated at 37°C in 
5% CO2. Supernatants were harvested at 24h p.i. and analyzed for the 
presence of IFN-α, TNF-α, IL-1β and IL-6.  
 
6.3.4. Cytokine measurement in cell-culture supernatants 
 
For cytokine measurement (TNF-α, IL-1β and IL-6) a Luminex 100 system 
was used (Beadlyte Human Multi-Cytokine Detection System 2) according 
to the manufacturer’s instructions. The amounts of IFN-α/β were 
determined by quantitative cytokine-specific ELISA kits (PBL Biomedical 
Laboratories), following manufacturer’s instructions and shown as one 
representative of three independent experiments. 
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6.3.5. Immunization and challenge of mice 
 
Seven animals per group of 6 to 8-week-old female BALB/c mice were i.n. 
infected under ether anesthesia with the indicated viruses at 5 x 105 
TCID50/mouse or with serum-free Optipro media (control group). Three 
days post immunization, 3 animals per group were sacrificed to determine 
the viral load in lungs and nasal turbinates. For this purpose, a 10% tissue 
extract in SPGN buffer was prepared by grinding the tissue sample with a 
rotor homogenizer. The suspension was then centrifuged at 2000 x g for 
10 min and supernatants were analyzed for viral yield by TCID50/ml. Blood 
was collected from the murine retro-orbital venous plexus 29 days 
following priming, the sera were prepared and stored at -20°C. The 
remaining animals were challenged with influenza NS1 wt strain (5 x 105 
TCID50/mouse) 32 days post immunization and were sacrificed 3 days post 
challenge to analyze the viral load in their lungs as described above.  
 
6.3.6. Influenza-specific IgG ELISA 
 
96-well microtiter plates were coated with influenza B/Thüringen/02/06 
adjusted to 50 HA units per well in a carbonate buffer (pH 9.6). Coated 
plates were incubated over night at 4°C, then washed with PBS containing 
0.1% Tween20 (PBS/Tween) and blocked with PBS/Tween plus I-block 
(Applied Biosystems) 5mg/ml (PBS/Tween/I-block). Serial dilutions of sera 
from immunized and, as a control, from naïve mice in PBS/Tween/I-block 
were applied to the plates (50µL/well) and incubated for 1.5h at room 
temperature. After washing, secondary rabbit anti-mouse IgG1 or IgG2a 
antibodies conjugated with horseradish peroxidase (Invitrogen) were 
added. After an additional washing step, plates were stained with Ultra-
TMB substrate (Thermo). The reaction was stopped with 4M H2SO4 and 
absorbance was measured at a wavelength of 450nm. The cut-off value 
was defined as the mean value of absorption of blank plus three standard 
deviations and shown as one representative of two independent 
experiments. 
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6.4. RESULTS 
 
Rescue of influenza B mutant viruses encoding C-terminally 
truncated NS1 proteins in Vero cells. Eight plasmids expressing HA 
and NA from B/Thüringen/02/06 and the remaining six genes from 
B/Vienna/33/06 master strain were used to generate influenza B virus 
NS1 truncation mutants by reverse genetics. We found that this 6:2 gene 
constellation leads to high rescue efficiency in Vero cells (data not shown). 
Translation of NS1 was terminated by two consecutive in-frame stop 
codons at aa positions 14, 38, 57 and 80, respectively. The non-translated 
part downstream of the stop codons up to the splicing signal of NS2/NEP 
was deleted to prevent reversion to wt NS1. A schematic representation of 
the constructs is shown in Fig. 1a. The NS1 truncation mutants were 
rescued in Vero cells as was the recombinant wt virus. The resulting 
rescued truncation viruses containing the N-terminal NS1-specific 14, 38, 
57 and 80 aa, respectively, were designated NS1-14, NS1-38, NS1-57, 
NS1-80 and NS1-wt. The different sizes of the NS gene of generated 
mutant viruses analyzed by RT-PCR confirmed the identity of the specific 
truncation as shown in Fig. 1b. Despite several attempts, we did not 
succeed in rescuing a ∆NS1-B virus, in which the ORF of NS1 is completely 
deleted and NS2/NEP is expressed as monocistronic mRNA.  
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Figure 1:  Generation of recombinant wt influenza B virus and NS1 truncation 
mutants. (A) Schematic representations of the NS genes and NS specific mRNAs of the 
wt, NS1-14, NS1-38, NS1-57 and NS1-80 truncation viruses. The asterisks (**) indicate 
two consecutive in frame stop codons. The part downstream of the stop codons up to the 
splicing signal of NEP/NS2 was deleted. (B) RT-PCR analysis of viral NS segments. RNA 
was isolated from the wt influenza B virus and from the NS1 truncated viruses and the 
NS segments were reverse transcribed and amplified by PCR. The resulting products 
were separated on a 2% agarose gel and stained with ethidium bromide. Sizes are 
indicated. 
 
 
Influenza B NS1 truncation mutants replicate efficiently in IFN-
deficient Vero cells but are attenuated in A549 cells and MEFs of 
PKR ko mice. NS1 truncation mutants and wt virus were evaluated for 
their potential to grow in IFN-competent A549 and IFN-deficient Vero cells 
(Fig. 2a+b). All NS1 truncation mutants showed similar growth kinetics in 
Vero cells reaching titers in the range of 107 to 108 TCID50/ml, which are 
comparable to those found with the wt virus. Replication of NS1-truncated 
viruses was severely attenuated in IFN-competent A549 cells as compared 
to Vero cells. While NS1-wt virus replicated to high titers of 4.4 x 107 
TCID50/ml, the growth of NS1-80 virus was significantly impaired with a 
difference of approximately 4 orders of magnitude. The NS mutants 
expressing an NS1 protein of less than 80 aa were even more attenuated 
showing almost complete restriction in growth in A549 cells with titers 
close to or below the detection limit of 2 x 102 TCID50/ml. Similar results 
were observed in human macrophages where only wt virus was able to 
replicate to 6 logs and all NS mutants did not replicate (data not shown). 
In the next step we investigated whether knocking out PKR, an antiviral 
protein known to be counteracted by the N terminal domain of the 
influenza B NS1 protein, is sufficient to restore viral growth in interferon 
competent cells. Therefore, we compared the truncated viruses’ ability to 
grow in mouse embryonic fibroblasts derived from PKR ko mice (Fig. 2c). 
This cell line supported the growth of wt virus of more than 7 logs. The 
NS1-80 virus replicated almost to wt levels whereas NS truncation 
mutants expressing a NS1 protein of less than 80 aa showed reduced 
growth properties by approximately 3 logs.  
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Figure 2: Growth properties of wt influenza B virus and NS1 truncation mutants 
in different cell lines. Confluent monolayers of (A) A549 cells, (B) Vero cells and (C) 
PKR knock out MEFs were infected with indicated viruses at an MOI of 0.01 and incubated 
at 33°C. At different time points, supernatants were harvested and the infectious titer 
was determined by TCID
50
/ml. All values below the detection limit of 1*102 TCID
50
/ml 
were considered to be 100. 
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Influenza B NS1 truncation mutants induce antiviral and pro-
inflammatory cytokines in macrophages and human nasal 
epithelial cells. It is well known that wt influenza viruses are able to 
antagonize type 1 IFN response as well as cytokine release from infected 
cells in various cell types (Dauber et al., 2004, Dauber et al., 2006, 
Egorov et al., 1998, Garcia-Sastre et al., 1998, Stasakova et al., 2005). In 
order to demonstrate the influence of influenza B virus NS1 protein on 
cytokine regulation we evaluated the potential of the NS1 truncation 
mutants NS1-14, NS1-38, NS1-80 and NS1-wt virus to induce IFN-α or 
IFN-β and major pro-inflammatory cytokines (TNF-α, IL-6 and IL1β) in 7-
day-old human macrophages and primary nasal epithelial cells, 
respectively. The NS1-wt virus was fully competent to inhibit the release 
of IFN-α/β, TNF-α, IL-1 β and IL-6 whereas all NS1-truncated viruses 
induced markedly higher levels of indicated cytokines in both, 
macrophages and nasal epithelial cells (see Fig. 3). Although the NS1-80 
mutant virus showed intermediate growth capacity in interferon 
competent cells, it seems that the first 80 aa of NS1 are not sufficient to 
block the activation of IFN and other pro inflammatory cytokines.  Our 
data imply that carboxy-terminal deletions of the NS1 protein of influenza 
B viruses are associated with the loss of functions responsible for 
inhibiting pro-inflammatory and antiviral cytokine production in human 
macrophages and nasal epithelial cells. 
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Figure 3: Cytokine release in human macrophages and HNEC infected with wt 
influenza B virus or NS1 truncation mutants. Human macrophages (black bars) and 
HNEC (white bars) were infected at an MOI of 2 with indicated viruses. Supernatants 
from infected cells were harvested 24h p.i. and assayed for TNF-α, IL-1β, IL-6 and IFN-α 
for macrophages and IFN-β for HNEC, respectively. One representative of three 
independent experiments is presented as a mean of two measurements +/- SEM. Mock 
value is subtracted. 
 
 
Influenza B NS1 truncation mutants are replication-deficient in 
mice. Due to the attenuated replication pattern in A549 cells we used a 
mouse model to examine whether the same attenuating effect was 
observable in vivo. 6 to 8-week-old female BALB/c mice were infected i.n. 
with 5 x 105 TCID50/mouse with either NS1 truncation or wt virus. Viral 
titers in lungs and nasal turbinates of mice were measured by TCID50/ml 
of a 10% tissue homogenate in Vero cells 3 days p.i. The geometric mean 
titers are shown in Table 1. The influenza B NS1-wt virus was replicating 
to a titer of 3.83 x 104 TCID50/ml of 10% tissue homogenate in lung tissue 
and 6.29 x 103 TCID50/ml in nasal turbinates. All NS1-truncated viruses 
failed to be re-isolated from lungs and nasal tissue, which indicates a 
replication-deficient phenotype. 
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TABLE 1: Replication of wt influenza B virus or NS1 truncation mutants in mice 
  
TCID50/ml 
Virus Lung 
Nasal 
turbinates 
NS1-14  n.d.* n.d. 
NS1-38 n.d. n.d. 
NS1-57 n.d. n.d. 
NS1-80 n.d. n.d. 
NS1-wt 3,83 x 104 6,29 x 103 
Control n.d. n.d. 
* not detectable 
 
Influenza B NS1 truncation mutants induce virus specific IgG 
response in mice. Subsequently, we investigated whether the 
replication-deficient NS1 truncation mutants induce a humoral immune 
response in mice. Animals immunized with any of the NS1 mutant viruses 
showed substantial virus-specific serum antibody levels even after one 
single i.n. immunization as determined by serum ELISA 29 days post 
immunization (Fig. 4). Differently to influenza B wt virus, a tendency to 
polarize the immune response towards Th1 was detected for the NS1 
truncation mutants, reflected by a predominance of IgG2a antibodies over 
IgG1. Serum of non immunized control mice did not yield in any 
significant titer and did not show any polarization effect. 
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Figure 4: Detection of virus specific IgG1/IgG2a in serum of primed mice. 
BALB/c Mice were immunized i.n. with indicated viruses (5*105 TCID
50
/mouse) or 
medium as a control. Serum samples were obtained 29 days after immunization. Virus 
specific IgG1 and IgG2a geometric mean titers were determined by ELISA and presented 
as one representative of two independent experiments. 
 
 
Mice are protected against wt virus challenge after one single 
immunization with NS1 truncation mutants. To investigate whether a 
single, i.n. immunization of the replication-deficient NS1 truncation 
mutants induces protective immunity, mice were challenged with 5 x 105 
TCID50/mouse of homologous influenza NS1-wt 32 days post 
immunization. The challenge virus was derived from a human isolate and 
did therefore not induce any symptoms such as body weight loss or 
lethality in mice (data not shown). Mice were sacrificed 3 days post 
challenge and viral titers were determined in lungs and reported as 
geometrical mean titers (GMT) TCID50/ml of a 10% tissue homogenate. 
Upon challenge with NS1-wt virus, none of the naïve mice was protected 
against infection, as indicated by viral loads of 2.47 x 104 TCID50/ml in 
lung tissue.  In contrast all mice immunized either with NS1-wt virus or 
with any of the NS1-truncated viruses were completely protected as 
demonstrated by the absence of detectable challenge viruses in their 
lungs (Table 2).   
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TABLE 2: Protection of mice immunized with influenza B truncation mutants 
against wt influenza B challenge 
  
Lung 
Virus for 
immunization 
  
TCID50/ml 
No. 
protected§/ 
total no. 
NS1-14  n.d.* 4/4 
NS1-38 n.d. 4/4 
NS1-57 n.d. 4/4 
NS1-80 n.d. 4/4 
NS1-wt n.d. 3/3 
Control 2.47 x 104 0/4 
* not detectable 
§ Mice with a titer below the detection limit of 1x102 TCID50/ml are considered as 
protected. 
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6.5. DISCUSSION 
 
 Seasonal influenza vaccines need to protect against circulating type 
A and type B influenza viruses. The purpose of this study was to develop 
contemporary, genetically defined and attenuated influenza B vaccine 
strains for production in certified Vero cells, implying that rescued strains 
are suitable for i.n. immunization of humans. It was previously shown that 
influenza A viruses with carboxy-terminally truncated NS1 proteins of 
different lengths are attenuated in such IFN-competent systems as MDCK 
cells and mice. Their attenuation was depended on the length of their NS1 
proteins but they were able to replicate to high titers in IFN-incompetent 
Vero cells (Egorov et al., 1998). This directly proved the role of A/NS1 in 
IFN antagonism. In a similar approach we developed a reverse genetic 
system employing contemporary influenza B virus adapted to high growth 
in Vero cells and generated a set of recombinant influenza B viruses with 
C-terminal deletions in their NS1 protein. The resulting viruses comprise 
NS1 proteins ranging from 14 to 80 aa, resulting in a loss of the complete 
functional RBD (Wang & Krug, 1996).  
Our data show that the generated influenza B mutant viruses lacking a 
functional NS1 protein are capable to grow in IFN-deficient Vero cells and 
are highly attenuated in IFN-competent A549 cells, which is in accordance 
with data found for influenza A virus. This demonstrates that even though 
the influenza A and B virus NS1 proteins share only limited sequence 
homology and differ considerably in their regulatory functions, their major 
function of antagonizing the host’s innate immune system is similar. 
We show that the deletion mutant NS1-80 replicates to high titers in PKR 
ko MEFs but is attenuated in A549 cells. This indicates that PKR is one 
major viral growth restricting factor. This finding is in accordance with the 
data published by Dauber et al., who demonstrated that influenza B 
mutants with impaired RNA-binding capacity cannot block the activation of 
PKR and are therefore highly attenuated in IFN-competent cells (Dauber 
et al., 2006). Hence, the genetic inactivation of PKR is sufficient to largely 
rescue efficient replication of the NS1-80 virus. In contrast, deletion 
mutants shorter than 80 aa were highly attenuated in PKR ko MEFs. We 
 47 
hypothesize that antiviral mechanisms other than PKR might be involved 
and that the N-terminal 80 aa of NS1 are sufficient to antagonize them. 
Mx and ISG15 could be excluded from the other IFN-induced antiviral 
proteins known to interact with influenza replication, because the former 
is not expressed in cells derived from most laboratory mice strains and the 
latter one is expected not to be recognized by B/NS1 protein of 80 aa 
(Yuan & Krug, 2001). Whether activation of 2’,5’-OAS or other antiviral 
proteins can be blocked by the partial function of the N-terminal 80 aa of 
B/NS1 remains to be investigated.  
We were able to rescue an influenza B virus expressing an NS1 protein as 
short as 14 amino acids, which we assume to have no function. However, 
we failed to generate an influenza B virus completely lacking the NS1 
open reading frame, in which the NS2/NEP is expressed from a 
monocistronic and not from a spliced mRNA. Dauber et al. generated a 
∆NS1 influenza B/Lee/40 virus (∆NS1-B), which did not grow in 11-day-old 
embryonated eggs but could be propagated in 6-day-old eggs that have a 
premature immune system (Dauber et al., 2004). It is not clear yet why 
∆NS1-B did not replicate in IFN-deficient Vero cells, while the analogous 
influenza A ∆NS1 virus did. One reason why the influenza B NS1-14 virus 
but not ∆NS1-B is able to replicate in Vero cells may be the lack of a 
natural splice site in ∆NS1-B, potentially leading to overexpression of 
NS2/NEP mRNA and resulting in a disregulation of nuclear export function 
or in a disparity in the cellular processing of spliced to unspliced protein 
(Reed & Cheng, 2005). We speculate that this change in the expression 
strategy of NS2/NEP could be compensated by other viral genes and that 
it might be possible to adapt a ∆NS1-B virus to replicate in Vero cells. 
It was shown previously that influenza A mutant viruses lacking the NS1 
gene or expressing a NS1 protein with an impaired RBD and dimerization 
domain induce 10-50 times higher levels of pro-inflammatory cytokines in 
infected macrophages as compared to wt virus (Stasakova et al., 2005). 
For type B viruses the amino acids downstream of NS1 position 104 were 
found essential for the control of hyper-induction of IFN-α/β in a 
continuous epithelial cell line (Dauber et al., 2006). The current study 
highlights the general importance of the B/NS1 protein in downregulating 
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pro-inflammatory and antiviral cytokines as shown by higher levels of IFN-
α/β, TNF-α, IL-6 and IL1-β of the influenza B NS1 truncation mutants as 
compared to wt virus in macrophages and primary human nasal epithelial 
cells.  
This report is the first description of a targeted approach to generate live 
influenza B vaccine strains whose attenuation mechanism is based on the 
partial deletion of the NS1 protein. The generated influenza B NS1 mutant 
viruses can be used for further clinical development of an i.n. 
administered live attenuated vaccine. They offer the advantage of being 
completely replication-deficient and not provoking any shedding. 
Immunized animals were completely protected from wt virus challenge in 
mouse lungs irrespectively of the length of the remaining NS1.  
We could show that mice receiving one single dose of replication-deficient 
virus induced anti-influenza IgG titers and had the tendency to polarize 
the immune system towards Th1, which is considered the best correlate of 
protectivity against viral infection (Proietti et al., 2002, Tovey et al., 
2008). Due to the lack of a functional NS1 protein, an increased local 
production of cytokines and chemokines potentially stimulates the 
humoral and cellular arm of the immune system. Because most 
inactivated vaccines are dependent on an adjuvant for stimulating such a 
response, we propose to call this phenomenon “self adjuvanting effect”.  
Our data emphasize that IFN-sensitive influenza B viruses with truncations 
in their NS1 gene can be efficiently produced in Vero cells and are 
immunogenic in animals. This presents a new perspective for further 
vaccine development strategies.  
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7.1. ABSTRACT 
 
We discovered a unique, single amino acid mutation in the influenza B M1 
protein promoting viral growth of NS1 truncation mutants in Vero cells. 
Due to this mutation, we were able to generate an influenza B virus 
lacking the complete NS1 open reading frame (∆NS1-B virus) by reverse 
genetics, which was growing to titers of 8 log10TCID50/ml in a Vero cell 
culture-based micro-carrier fermenter. The ∆NS1-B vaccine candidate was 
attenuated in IFN-competent hosts such as human alveolar epithelial cells 
(A549) similar to influenza A ∆NS1 viruses. In ferrets, the ∆NS1-B virus 
was replication-deficient and did not provoke any clinical symptoms. 
Importantly, a single intranasal immunization of ferrets at a dose as low 
as 6 log10 TCID50/animal induced a significant HAI response and provided 
protection against challenge with wild-type influenza B virus. So far, the 
lack of a ∆NS1-B virus component growing to high titers in cell culture has 
been limiting the possibility to formulate a trivalent vaccine based on 
deletion of the NS1 gene. Our study closes this gap and paves the way for 
the clinical evaluation of a seasonal, trivalent, live replication-deficient 
∆NS1 intranasal influenza vaccine. 
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7.2. INTRODUCTION 
 
Influenza A and B viruses cause severe respiratory illness and have a 
tremendous social and economic impact. Responsible for thousands of 
deaths and hospitalizations per year in Europe alone, influenza viruses 
continue to be a major health concern (EISS, 2006). Whereas influenza A 
viruses have a high epidemiological impact, influenza B viruses are more 
associated with complications like Reye’s syndrome and encephalitis in 
children (Lin et al., 2006, McCullers et al., 1999). Although antiviral drugs 
have already been licensed for human application, vaccination remains the 
primary strategy for preventing and controlling influenza.  
Current influenza virus vaccines consist of three components, namely the 
influenza B component, influenza A H1N1 and H3N2. Due to antigenic drift 
the WHO recommends the strains to be included into the vaccine 
formulation semi-annually. For 2008/2009, all three components of the 
trivalent vaccine were changed to influenza A/Brisbane/53/2007 (H1N1), 
A/Brisbane/10/2007 (H3N2) and B/Florida/4/2006 for the northern 
hemisphere.  
At present, two types of licensed influenza vaccines are available, 
inactivated (TIV) and live cold-adapted (ca) attenuated influenza vaccines 
(LAIV). Despite comparable efficacies of both TIVs and LAIVs (Belshe et 
al., 2008, Fleming et al., 2006, Treanor et al., 1999), LAIVs have the 
advantage of needle-free administration via the nasal mucosa and hence 
provoke a different spectrum of the immune response. While TIVs induce 
overall higher serum antibody titers, LAIVs elicit specific mucosal IgA 
antibodies at the site of virus entry, thereby helping to prevent infection 
before viral replication can occur (Doherty et al., 2006, Nichol, 2001, 
Nichol & Treanor, 2006). It is reported that LAIVs induce a longer lasting, 
broader and more protective immune response and the involvement of 
virus-specific T-cells and the induction of secretory IgA antibodies in the 
nasal mucosa suggests better cross-protection against antigenic drift 
variants (Belshe et al., 2000, Beyer et al., 2002, Cox et al., 2004, Ferko et 
al., 2004, Nichol & Treanor, 2006, Tamura et al., 2005). Although LAIVs 
are considered to be sufficiently safe, they clearly have the disadvantage 
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of viral replication in the upper respiratory tract resulting in shedding from 
vacinees. Particularly cold-adapted influenza B virus was shown to 
replicate up to 21 days after immunization in children(Vesikari et al., 
2006b).  
Alternative live attenuated vaccine approaches for influenza viruses have 
been developed, for instance, by altering the viral IFN antagonist, i.e. the 
NS1 protein, by reverse genetics (Egorov et al., 1998, Garcia-Sastre et 
al., 1998). Influenza A viruses with impaired NS1 function are not able to 
counteract the host’s innate immune response (Hale et al., 2008). It was 
demonstrated that influenza A viruses with large C-terminal truncations in 
the NS1 protein are attenuated and induce protection in animals (Ferko et 
al., 2004, Kochs et al., 2007, Quinlivan et al., 2005, Solorzano et al., 
2005). An influenza A virus devoid of the NS1 protein (∆NS1-A) was found 
to be completely replication deficient in animals and induces high amounts 
of pro-inflammatory cytokines, associated with activation of antigen 
presenting dendritic cells as well as virus specific B- and T-cell mediated 
immune responses (Egorov et al., 1998, Ferko et al., 2004, Talon et al., 
2000b). Recently, we performed a first-in-man study with a ∆NS1-A 
(H1N1) vaccine virus where the replication-deficient phenotype and high 
immunogenicity in humans was confirmed (Manuscript in preparation).   
Until now a ∆NS1 influenza B virus with high growth potential in tissue 
culture was not available. In this study, we discovered an adaptive 
mutation in the M1 protein enabling replication of an influenza B virus in 
which the NS1 ORF was completely deleted (∆NS1-B) to high titers of 8 
log10 TCID50/ml in a Vero cell culture-based micro-carrier fermenter. At the 
same time the virus was replication-deficient and apathogenic in animals. 
We demonstrate that ferrets immunized once intranasally with the ∆NS1-B 
vaccine candidate at a dose of 6 log10 TCID50/animal elicited a systemic 
antibody response and were protected against challenge with wild-type 
virus after one single intranasal administration. 
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7.3. MATERIALS AND METHODS 
 
7.3.1. Cells, viruses and viral infections 
 
Vero cells (ATCC CCL-81) were used for transfection experiments, 
propagating viruses and virus titrations. Vero cells were adapted to and 
cultivated in serum-free OptiPro media (Invitrogen) with 4mM L-glutamine 
(Gibco). A549 cells (ATCC CCL-185) were cultivated in Dulbecco-modified 
Eagle medium (DMEM; Gibco) and used for growth curves of rescued 
viruses. Influenza B/Vienna/23/07 virus subtyped as influenza 
B/Florida/04/06, B/Vienna/33/06 subtyped as B/Malaysia/2506/04 were 
provided by M. Redlberger (Institute of Virology, Vienna, Austria) and 
B/Thüringen/02/06 virus subtyped as influenza B/Jiangsu/10/03 was 
obtained from B. Schweiger (German National Reference Center for 
Influenza; Robert Koch Institute, Berlin, Germany). For easier distinction, 
viruses were named according to the subtype of their HA and NA genes as 
B/Florida, B/Malaysia and B/Jiangsu, respectively. Influenza 
A/Vienna/28/06 virus subtyped as influenza H3N2 A/Wisconsin/67/05 and 
A/Vienna/414/07 subtyped as influenza H1N1 A/Brisbane/59/07 were 
provided by M. Redlberger (Institute of Virology, Vienna, Austria). The 
IVR-116 vaccine strain, a reassortant of influenza A/New Caledonia/20/99 
and A/Puerto Rico/8/34 (PR8) viruses, was obtained by the WHO. All 
viruses were adapted to grow on serum-free Vero cells. To propagate 
viruses and to determine viral replication, indicated cells were washed 
with phosphate-buffered saline (PBS) and incubated with virus at the 
indicated multiplicities of infection (MOI) at room temperature for 30 
minutes. Inoculum was removed, serum-free OptiPro media containing 
5µg/ml Trypsin (Sigma) and 250ng/ml Amphotericin B (Brystol Meyers) 
was added and cells were incubated at 33°C for influenza B or 37° for 
influenza A viruses and 5% CO2. After the indicated time points, the 
supernatant of infected cells was analyzed for viral titer by TCID50.  
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7.3.2. Generation of NS1-truncated viruses 
 
HA and NA genes of B/Florida virus and the remaining 6 genes of 
B/Jiangsu or all 8 genes of B/Malaysia including non-coding regions were 
sequenced and each cloned into vector phW2006, a synthetically produced 
vector similar to pHW2000 (Hoffmann et al., 2002), generated by 
GENEART (Regensburg, Germany). The vector contains PolI/PolII 
promoter and terminator sequences for the bicistronic expression of 
influenza genes. To generate the NS1 truncation mutants, the plasmid 
encoding the NS gene was modified by site-directed mutagenesis 
(Stratagene) to express an NS1 protein of 38 and 80 aa, respectively. 
Translation was terminated by two consecutive in-frame stop codons. The 
cDNA downstream of the stop codon cassette up to the splicing signal of 
NS2/NEP (position 634nt) was deleted by inverse PCR. Inverse PCR was 
performed to obtain a plasmid coding for an NS gene segment, in which 
the complete open reading frame of NS1 is deleted (nt position 78-731). A 
mutation in the plasmid encoding the M gene at nt position 281 (A-G) 
resulting in a change at amino acid position 86  of the M1 protein from 
valine to methionine was introduced in a similar way. All viruses were 
rescued by transfection on Vero cells as described previously (in press). 
Viruses used for growth curves and animal studies containing HA and NA 
of B/Florida and the remaining genes of B/Jiangsu comprising the M1-
M86V mutation were named according to the size of the NS1 protein, i.e. 
∆NS1-B and NS1-wt.  
For the generation of the influenza H1N1 and H3N2 vaccine strains, the 
NS1 open reading frame of influenza A viruses was deleted in a similar 
way (Garcia-Sastre et al., 1998). Rescued viruses containing HA and NA 
A/Vienna/414/07 or from A/Vienna/28/06, the ∆NS1 gene and the other 
genes from IVR116 were named as ∆NS1-H1N1 and ∆NS1- H3N2, 
respectively. The expected sequences of HA, NA and NS genes of rescued 
viruses were confirmed by nucleotide sequence analysis and, for NS, 
additionally by analyzing amplified RT-PCR products.  
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7.3.3. Production of influenza virus in Vero cell culture-based micro-
carrier fermenter 
 
Growth of influenza virus in Vero cells was as described elsewhere (Kistner 
et al., 1998). Briefly, a single aliquot of the fully characterized Vero 
production cell bank was expanded through successive passages to the 
required volume in serum-free DMEM/Ham’s F12 medium. 15 L-scale 
fermenters containing microcarrier cultures were infected with an aliquot 
of the ∆NS1-B influenza virus at an MOI of 0.005. Incubation was carried 
out at 34°C for 3-4 days using trypsin at a concentration of 20 mU/ml. 
Supernatant virus was harvested, clarified and analyzed for HA and 
TCID50. 
 
7.3.4. Immunization and challenge of ferrets 
 
Ferrets were housed individually at 15°C–21ºC, a relative humidity of 30–
70% and a 12:12 light:dark cycle. Food (Catmix complete, Dibaq, Czech 
Republic) and water were provided ad libitum. Four to five animals per 
group of 5 to 8-months-old male and female ferrets (Mustela putorius 
furo) were intranasally (i.n.) infected under anaesthesia (Ketamin 
20mg/kg + Medetomidine 0.04mg/kg, i.m.) at 1 x 106 TCID50/ferret with 
either monovalent influenza B virus ∆NS1-B vaccine or with 1 x 106 
TCID50/ferret of each strain ∆NS1-B, ∆NS1-H1N1 and ∆NS1-H3N2 
(trivalent formulation) or PBS (control group). Ferrets were monitored 
daily for clinical signs such as sneezing and nasal discharge and body 
temperature and body weight were recorded. Nasal washes were taken 
from all animals on days 3 and 5 for analysis of viral replication in tissue 
culture. Blood was collected 4 days prior and 29 days after immunization, 
sera were prepared and further used for the hemagglutination inhibition 
assays. On day 37 post immunization animals were challenged with 
influenza B NS1-wt strain (1 x 106 TCID50/ferret) and nasal washes were 
taken on days 3 and 5 post challenge to determine the viral load as 
described above. This animal study was approved by the Animal Care and 
Use Committee (IACUC) of BioTest Ltd. and the Committee for Animal 
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Protection of the Ministry of Industry and Trade of the Czech Republic 
(35/2007). 
 
7.3.5. Hemagglutination inhibition (HAI) assay 
 
Serial twofold dilutions of ferret sera pre-treated with receptor-destroying 
enzyme (RDE) were prepared in a 96-well micro titer plate and 25µl 
containing 4 HA units of homologous antigen was added to each well. 
After an incubation period of 30 minutes at room temperature, 50µl of 
chicken erythrocytes (0.5%, derived from adult chicken blood) were 
added. Results were recorded after incubation at 4°C for 60 minutes. The 
HAI titration end point was determined by the highest dilution of 
antiserum that still inhibits complete hemagglutination of RBCs. The 
presented value is the reciprocal of the last serum dilution inhibiting virus 
hemagglutination. A titer of 1:8 was considered to be negative. Values 
from the monovalent and trivalent ∆NS1-B groups were each compared to 
the PBS group by Mann-Whitney U test. 
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7.4. RESULTS 
 
Generation of influenza B NS1 mutant viruses on Vero cells  
Influenza B NS1 mutants were generated by reverse genetics on Vero 
cells using 8 plasmid rescue system as described previously (Hoffmann et 
al., 2002, Kittel et al., 2005). Initial rescue experiments with B/Malaysia 
NS1-80 and NS1-wt virus showed clear cytopathic effects (CPE) three to 
four days post transfection whereas NS1-38 only showed weak CPE after 3 
blind passages on Vero cells (data not shown). Higher growth of the NS1-
38 virus was observed after further passaging on Vero cells suggesting 
that an adaptive mutation had occurred. Sequencing of the whole virus 
genome of NS1-38 revealed a single coding mutation in the M1 gene at 
nucleotide position 281, corresponding to an amino acid change at 
position 86 from methionine to valine (Fig. 1A). A sequence query showed 
that the M1-M86V mutation is a unique mutation not present in any other 
published viral M1 sequence (Fig. 1). Reintroduction of the M1-M86V 
mutation into the B/Malaysia backbone confirmed the effect of this 
mutation in boosting the viral growth of a NS1-38 mutant virus (data not 
shown).  
 
 
Figure 1: Sequencing diagramm of M 
genes of influenza B/Malaysia-swab and 
B/Malaysia-adapted virus and comparison 
with other influenza B viruses. 
(A) A B/Malaysia virus containing an 
NS1 protein of 38aa was rescued on 
Vero cells, passaged and the M gene of 
the B/Malaysia-adapted was compared 
by sequencing to the parental wt strain. 
One nucleotide difference at position 
281 resulting in an amino acid change 
at position 86 (M86V) was found. 
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To evaluate the impact of the M1-M86V mutation on other influenza B 
strains, we introduced this mutation into a different viral backbone. We 
created a reverse genetic rescue set based on the B/Jiangsu master strain 
containing HA and NA glycoproteins of B/Florida, the WHO 
recommendation for the year 2007/08. The M1-M86V substitution slightly 
improved the growth of NS1-wt virus when compared to the wt M gene 
construct (Fig. 2B). However, viral titers for the NS1-38 and NS1-80 
mutants containing the M1-M86V mutation were approximately 4 or 2 logs 
higher than wt M1 analogs, respectively. Due to the M1-M86V mutation, 
we were able to rescue for the first time a ∆NS1-B virus reaching titers of 
almost 4 logs 5 days post transfection on Vero cells. These data 
demonstrate that the M1-M86V mutation compensates for a dysfunctional 
NS1 protein and is essential for rescuing a ∆NS1-B virus growing to high 
titers on Vero cells, in which the NS1 ORF is completely deleted. 
 
 
  
Figure 2: Viral titer of recombinant influenza B viruses containing wt or M86V M gene after 
transfection. Supernatant of indicated viruses was harvested 5 days post transfection 
containing the M gene as indicated. Titer was measured by TCID50 on Vero cells. 
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Influenza ∆NS1-B virus is attenuated in A549 cells but replicates 
efficiently in a Vero cell culture-based micro-carrier fermenter 
In order to demonstrate the interferon sensitive phenotype of ∆NS1-B 
virus, we examined its ability to grow on IFN-competent A549 and IFN-
deficient Vero cells in comparison to the corresponding wt virus (Fig. 3). 
Both viruses showed comparable growth kinetics on Vero cells, reaching 
titers in the range of 107 to 108 TCID50/ml. Replication of ∆NS1-B virus 
was completely restricted in IFN-competent A549 cells, which displayed no 
growth above the detection limit of 2 x 102 TCID50/ml, while NS1-wt virus 
replicated to high titers of 3.15 x 108 TCID50/ml. Mutant viruses NS1-80 
and NS1-38 showed intermediate replication capacity (in press).  
 
 
 
Figure 3: Growth properties of influenza B viruses in Vero and A549 cell lines. Confluent 
monolayers of (A) Vero cells and (B) A549 cells were infected with indicated viruses at an 
MOI of 0.01 and incubated at 33°C. At different time points, supernatants were 
harvested and the infectious titer was determined by TCID50. All values below the 
detection limit of 1 x 102 TCID50 were considered to be 10
0. 
 
 
Furthermore we could demonstrate that the ∆NS1-B vaccine candidate 
could be efficiently produced in a Vero cell culture-based micro-carrier 
fermenter (Table 1). In three independent 15L fermenter runs the ∆NS1-B 
virus yielded HA titers of 48 and infectious titers were ranging from 7.80 
+/- 0.19 to 8.00 +/- 0.25 log10 TCID50/ml. These titers were equal or even 
higher than the titers obtained in monolayer Vero cell culture. We 
demonstrate that the ∆NS1-B virus can be successfully produced in Vero 
cell culture-based micro-carrier fermenter reaching high titers of 8 log10. 
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TABLE 1: Hemagglutination and TCID50 titers of ∆NS1-B vaccine in  three 
independent GMP fermentations                                                                                                                                                                                                          
  
Fermentation 
Clarified 
GMP 
harvest 
Log10TCID50/ml HAU
a/50µl 
Batch 1 8.00 +/- 0.25 48 
Batch 2 7.80 +/- 0.19 48 
Batch 3 7.95 +/- 0.33 48 
aHemagglutinating Units 
 
Influenza ∆NS1-B vaccine is replication-deficient and safe in 
ferrets 
In view of the attenuated replication pattern in A549 cells, we used the 
ferret model to examine whether the same attenuating effect was 
observable in vivo. 5 to 8-months-old male and female ferrets (Mustela 
putorius furo) were infected i.n. with ∆NS1-B virus at a dosage of 1 x 106 
TCID50/ferret. Viral titers in the nasal washes of animals were measured 
by TCID50/ml on Vero cells 2 days p.i. No virus could be recovered for 
∆NS1-B virus indicating a replication-deficient phenotype without any 
vaccine virus shedding (data not shown). Moreover all animals were 
monitored daily for clinical symptoms and activity status 
(inactivity/lethargy). No respiratory symptoms such as coughing, nasal 
discharge, sneezing and dyspnoe could be observed for the vaccine group, 
nor were any neurological symptoms such as ataxia, limb paresis, 
torticollis or abnormal behavior detectable. No changes in body weight 
and body temperature were recorded (data not shown). These data 
indicate that the ∆NS1-B vaccine candidate is safe. 
 
 
Influenza ∆NS1-B vaccine is immunogenic in ferrets  
Subsequently, we investigated whether the ∆NS1-B vaccine virus induces 
a systemic antibody immune response in ferrets. Animals were immunized 
with the monovalent vaccine containing 1 x 106 TCID50/ferret of ∆NS1-B 
virus. In order to study the interference with influenza A ∆NS1 mutant 
viruses in a trivalent formulation, another group of animals was 
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vaccinated with the trivalent vaccine containing 1 x 106 TCID50/ferret of 
∆NS1-H1N1, ∆NS1-H3N2 and ∆NS1-B. Although higher doses would have 
been technically feasible since the ∆NS1-B vaccine strain was replicating 
to titers of 1 x 108 TCID50/ml, we chose a rather low immunization dose to 
challenge our vaccine concept. Immune response against the influenza B 
component was analysed by hemagglutination inhibition assay (HAI) 29 
days after immunization (Fig. 4). Ferrets receiving the monovalent ∆NS1-
B vaccine showed significant hemagglutination-inhibition titers after 
immunization when compared to the PBS group, ranging from 32 to 64 
(p<0.05). In the trivalent group the HAI response to the influenza B 
component was in the range of 8 to 16 (p<0.05 compared to the PBS 
group). Thus, to some extent an interference effect was detectable for the 
influenza B component (Fig. 4). However, this interference on the 
immunogenicity level did not affect protection against wild-type challenge 
(Fig 5).   
 
 
Figure 4: Hemagglutination 
inhibition assay of monovalent and 
trivalent vaccine. Sera from ferrets 
immunized with 1 x 106 TCID50/ferret of 
either monovalent ∆NS1-B virus ( ) or 
trivalent formulation ( ) were analyzed 
29 days after immunization for 
hemagglutination inhibition titers against 
influenza B wt virus and compared to 
PBS group ( ) (*P< 0.05). 
 
 
 
 
Influenza ∆NS1-B vaccine protects ferrets against wild-type virus 
challenge after one single immunization  
We investigated whether one single i.n. immunization at a dose of 6 log10 
TCID50/ferret with the ∆NS1-B virus induces protective immunity. Ferrets 
were vaccinated with either monovalent or trivalent ∆NS1-B formulation 
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and were challenged with 1 x 106 TCID50/ferret of homologous influenza 
B/Florida wt virus. Viral recovery of the nasal washings was chosen as the 
assessment criteria for protection since fever was not induced by 
challenge with wt virus. Samples were taken from ferrets on days 3 and 5 
post challenge and viral titers were determined by TCID50 assay.  
In all five naïve control ferrets the challenge virus was detectable on day 
3, as indicated by viral loads in the range of 3.59 x 101 to 1.47 x 103 
TCID50/ml in the nasal washes (Fig. 5). In contrast, three out of four 
ferrets immunized with either the monovalent ∆NS1-B vaccine virus or the 
trivalent formulation were fully protected showing no detectable challenge 
virus in nasal samples. A similar trend was observed on day 5 post 
challenge (Fig. 5). This finding demonstrates the effectiveness of the 
vaccine applied as monovalent or trivalent ∆NS1 virus preparation in 
protecting ferrets against challenge with wild-type virus after one single 
i.n. immunization. 
 
 
Figure 5: Viral recovery in nasal 
washes after challenge. Ferrets 
were i.n. immunized with 1 x 106 
TCID50/ferret of ∆NS1-B monovalent ( 
) or trivalent ( ) and PBS ( ) and 
challenged 37 days post inoculation 
with influenza B wt virus (1 x 106 
TCID50/ferret). Viral replication was 
analyzed 3 and 5 days post challenge. 
Titers in the nasal washes were 
determined as TCID50/ml and reported 
for every single ferret. Ferrets with a 
titer below the detection limit of 1 x 
101 TCID50/ml are considered as 
protected. 
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7.5. DISCUSSION 
 
This is the first description of a contemporary, live attenuated influenza 
∆NS1-B vaccine candidate strain whose attenuation mechanism is based 
on the deletion of the ORF of the NS1 protein and which is growing to high 
titers on Vero cells. Despite a replication deficient phenotype in ferrets, 
the monovalent ∆NS1-B and the trivalent vaccine formulation provoke a 
hemagglutination inhibition antibody response and protect animals from a 
homologous influenza virus challenge after one single intranasal 
immunization.  The trivalent vaccine formulation additionally contains an 
influenza A ∆NS1-H1N1 and ∆NS1-H3N2 component. Importantly, while 
titers where reaching 8 log10
 TCID50/ml in a Vero cell culture-based micro-
carrier fermenter, the immunogenic dose was as low as 6 log10 
TCID50/ferret. 
When adapting an influenza B virus with a truncated NS1 protein on Vero 
cells, we discovered a unique mutation in the M1 (M1-M86V) protein, 
which is not present in any other influenza B virus sequences submitted to 
the Genbank. Reintroduction of this mutation into two independent viral 
backbones of representatives of the B/Yamagata/16/88 and 
B/Victoria/2/87 (data not shown) lineages resulted in increased rescue 
efficiency of viruses expressing C-terminal-truncated NS1 proteins.  Only 
by inserting the M1 mutation we succeeded in generating a ∆NS1-B virus 
growing to high titers on Vero cells. Introducing the M1 mutation into the 
wt backbone resulted in slightly increased virus titers on Vero cells.  
Hence, the M1-M86V mutation might rather compensate for the loss of the 
functional NS1 protein than affecting Vero cell adaptation. The exact 
mechanism of the M1-M86V mutation remains to be further investigated. 
Dauber et al. described the generation of a similar ∆NS1-B influenza virus, 
in which the ORF of NS1 is completely deleted and the NS2/NEP protein is 
expressed as a monocistronic mRNA. This ∆NS1-B virus in the backbone of 
the egg-adapted B/Lee/40 strain showed severe attenuation compared to 
NS1 wild-type virus on IFN-deficient Vero cells reaching a titer of 2 logs 
(Dauber et al., 2004). Hai et al. generated an influenza B 
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(B/Yamagata/16/88) mutant virus with a truncated NS1 protein of 16 
amino acids length (described as deltaNS1) (Hai et al., 2008). This virus 
was also shown to be severely attenuated in growth in Vero and other 
cells by replicating to less than 4 log10. It was hypothesized that the NS1-
B protein plays an essential role in promoting high-level replication of the 
influenza B virus in both IFN-competent and IFN-deficient cell lines. Since 
high replication of vaccine viruses is crucial for commercial vaccine 
production, high titers in cell culture are mandatory. Our data show that it 
is feasible to produce a ∆NS1-B vaccine strain on certified Vero cells as 
demonstrated by titers of more than 8 log10 in a 15L Vero cell based 
microcarrier fermentation and that the NS1 protein of influenza B viruses 
is not needed for efficient replication in Vero cells, analogous to influenza 
A ∆NS1-A viruses. 
We believe that the advantages of a replication deficient ∆NS1-B vaccine 
to attenuated replicating vaccines are versatile. In our work we confirmed 
that the deletion of the NS1 ORF in the influenza B virus genome leads to 
a replication deficient phenotype in animals similar to influenza A viruses. 
It is controversially discussed whether lack of replication of the vaccine 
virus might be a limiting factor for induction of protective immune 
response. Despite their replication-deficiency, ∆NS1 viruses are competent 
to infect the host cell and initiate transcription and translation of viral 
proteins. We demonstrate that replication of an influenza B vaccine virus 
in the respiratory tract is not essential for the induction of HAI and 
protective immune response in ferrets. The immunogenicity and protective 
efficacy at the relatively low dose of 6 log10 TCID50/ml of ∆NS1-B viruses 
could be explained by their enhanced capacity to induce a local cytokine 
response at the site of vaccine application (Ferko et al., 2004). This “self 
adjuvant” effect potentially boosts the immune response and thereby acts 
as a natural adjuvant.  
Although intermediate NS1 truncation mutants appear to be better 
immunogenic than complete deletion mutants in the mouse model (Ferko 
et al., 2004, Hai et al., 2008), we did not observe significant differences in 
immunogenicity between intermediate and complete NS deletion mutants 
of influenza A vaccine candidates in the ferret or macaque model 
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(manuscript in preparation). Viruses with NS1 proteins of intermediate 
length are still able to at least partially replicate in the respiratory tract 
inducing viral shedding like LAIVs. It was shown that cold-adapted B 
vaccine strains could replicate in vaccinated children up to 21 days after 
immunization and that they could be transmitted from vaccine recipients 
to contact persons (Block et al., 2008, Dauber et al., 2006, Hai et al., 
2008, King et al., 2000, Talon et al., 2000b, Vesikari et al., 2006a). 
Therefore, it is recommended that individuals vaccinated with LAIV should 
not be in contact with immunosuppressed persons for 7 days after 
vaccination (King et al., 2000).  
Except for viral shedding, ∆NS1 vaccines share basic properties of LAIVs 
such as ease of intranasal administration, induction of a mucosal IgA 
immune response, initiation of a strong cytotoxic T-cell response and 
cross-protection (Ferko et al., 2004). Certainly the fast generation of seed 
viruses by reverse genetics and vaccine manufacturing in large quantities 
in tissue culture offer additional advantages over classical reassortants 
and production in eggs. Vero cells are an IFN-deficient, certified cell line 
suitable for vaccine production and promote growth of ∆NS1 to high titers. 
Our study underlines the feasibility of producing a live attenuated, 
trivalent influenza vaccine on Vero cells based on ∆NS1 technology. 
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8. Conclusion 
 
Despite the continuous improvement and advanced technologic 
developments of influenza vaccines, influenza viruses continue to be 
important pathogens with worldwide prevalence responsible for thousands 
of deaths and hospitalizations annually. 
Within this thesis several influenza B viruses with C-terminally truncated 
NS1 proteins of different length were generated employing reverse 
genetics on Vero cells to progress the development of live-attenauted 
vaccines. Recapitulating the results: 
(1) The rescued truncation mutants containing the N-terminal 14, 38, 57 
or 80aa of the NS1 protein were impaired in their ability to counteract IFN 
production, were able to grow to high titers in IFN-deficient Vero cells and 
are severely attenuated in IFN-competent hosts. (2) They induce pro-
inflammatory antiviral cytokines early after infection. (3) A NS1-80 virus 
displayed high growth on PKR knock-out mouse embryonic-fibroblasts, 
whereas NS1-truncated mutants with a NS1 protein shorter than 80aa 
were highly attenuated. This finding indicates that other antiviral 
mechanisms besides PKR might be involved and that the first 80aa of the 
NS1 protein are sufficient to antagonize these. Whether activation of 2’,5’-
OAS or other antiviral proteins can be blocked by the partial function of 
the N-terminal 80 aa of B/NS1 remains to be elucidated. (4) Mice 
receiving a single intranasal immunization of the NS1-truncated viruses 
elicited an antibody response and were protected from wild-type virus 
challenge. (5) A complete ∆NS1-B virus was feasible to rescue due to the 
introduction of a single mutation in the M1 gene. (6) It was shown that 
despite the lack of a function IFN-antagonizing protein NS1 this influenza 
B virus was growing to high titers in Vero cells and at the same time was 
replication deficient in IFN-competent hosts such as A549 cells and 
ferrets. (7)  A single intranasal immunization of ferrets at a dose as low as 
6 log10 TCID50/animal induced a significant HAI response and provided 
protection against challenge with wild-type influenza B virus. 
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In the scientific community it is controversially discussed whether a 
complete ∆NS1 virus or an intermediate mutant is more appropriate for 
application as a life vaccine. We believe that the advantages of a ∆NS1-B 
vaccine to intermediate NS1 mutant viruses are multifaceted. Viruses with 
NS1 proteins of intermediate length are still able to at least partially 
replicate in IFN-competent hosts (Dauber et al., 2006, Hai et al., 2008, 
Talon et al., 2000b). Some believes are that replication-competence in the 
host is a benefit in contrast to replication-deficiency (Hale et al., 2008), 
neglecting the fact that viral shedding like LAIVs is induced. It was made 
evident that cold-adapted B vaccine strains could replicate in vaccinated 
children up to 21 days after immunization and that transmission from 
vaccine recipients to contact persons occurs (Block et al., 2008, King et 
al., 2000, Vesikari et al., 2006a). Furthermore Talon et al. investigated 
the properties of two spontaneous influenza B virus mutants expressing 
110 and 89 amino acids of the NS1 protein, respectively. Both NS1 
mutant viruses replicated in mouse lungs up to 3 days after infection 
(Talon et al., 2000b). Hai et al. generated influenza B NS1 truncation 
viruses consisting of 16, 80 and 110 amino acids, respectively, which 
replicated up to 3 logs in mice. In contrast to these two studies, we were 
neither able to isolate shedding virus from ferrets immunized with ∆NS1-B 
which contains a complete deletion of NS1 nor could we detect any sign of 
replication on IFN-competent cells such as A549. Despite their replication-
deficiency, ∆NS1 viruses are competent to infect the host cell, initiate 
transcription and translation of viral proteins and induce HAI and a 
protective immune response in ferrets.  
This study underlines the applicability of a ∆NS1-B virus as a live 
attenuated influenza vaccine and emphasizes the feasibility of producing a 
trivalent vaccine. 
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9. Abbreviations 
 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO  Dimethylsulfoxide 
ELISA  Enzyme linked immunosorbent assay 
FCS   Fetal calf serum 
HA   Hemaglutinin 
HAI  Hemagglutination Inhibition Assay 
IgG   Immunglobulin G 
IL   Interleukin 
kDa   Kilo-Dalton 
M   Matrix protein 
NA   Neuraminidase 
NCR   Non coding regions 
NEP   Nuclear export protein 
NES   Nuclear export signal 
NLS   Nuclear localization signal 
NP   Nucleoprotein 
NS1   Non structural protein 1 
ORF   Open reading frame 
PA   Polymerase (acidic) 
PB1   Polymerase (basic) 1 
PB2   Polymerase (basic) 2 
PBS   Phosphate-buffered Saline 
PKR   Protein kinase R 
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